



DHS SCIENCE AND TECHNOLOGY

Master Question List for COVID-19 (caused by SARS-CoV-2)

Weekly Report

05 May 2020

For comments or questions related to the contents of this document, please contact the DHS S&T Hazard Awareness & Characterization Technology Center at HACTechnologyCenter@hq.dhs.gov.



**Homeland
Security**

Science and Technology

DHS Science and Technology Directorate | MOBILIZING INNOVATION FOR A SECURE WORLD

CLEARED FOR PUBLIC RELEASE

FOREWORD

The Department of Homeland Security (DHS) is paying close attention to the evolving Coronavirus Infectious Disease (COVID-19) situation in order to protect our nation. DHS is working very closely with the Centers for Disease Control and Prevention (CDC), other federal agencies, and public health officials to implement public health control measures related to travelers and materials crossing our borders from the affected regions.

Based on the response to a similar product generated in 2014 in response to the Ebolavirus outbreak in West Africa, the DHS Science and Technology Directorate (DHS S&T) developed the following “master question list” that quickly summarizes what is known, what additional information is needed, and who may be working to address such fundamental questions as, “What is the infectious dose?” and “How long does the virus persist in the environment?” The Master Question List (MQL) is intended to quickly present the current state of available information to government decision makers in the operational response to COVID-19 and allow structured and scientifically guided discussions across the federal government without burdening them with the need to review scientific reports, and to prevent duplication of efforts by highlighting and coordinating research.

The information contained in the following table has been assembled and evaluated by experts from publicly available sources to include reports and articles found in scientific and technical journals, selected sources on the internet, and various media reports. It is intended to serve as a “quick reference” tool and should not be regarded as comprehensive source of information, nor as necessarily representing the official policies, either expressed or implied, of the DHS or the U.S. Government. DHS does not endorse any products or commercial services mentioned in this document. All sources of the information provided are cited so that individual users of this document may independently evaluate the source of that information and its suitability for any particular use. This document is a “living document” that will be updated as needed when new information becomes available.

Table of Contents

Infectious Dose – How much agent will make a healthy individual ill?	3
<p>The human infectious dose of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is unknown by all exposure routes. SARS-CoV-2 is the cause of coronavirus disease 19 (COVID-19). The correlation between the infecting dose and symptom severity is unknown. Identifying the infectious dose for humans by the various routes through which we become infected is critical to the effective development of computational models to predict risk, develop diagnostics and countermeasures, and effective decontamination strategies. Animal studies are a plausible surrogate.</p>	
Transmissibility – How does it spread from one host to another? How easily is it spread?	4
<p>SARS-CoV-2 is passed easily between humans, likely through close contact with relatively large droplets and possibly through smaller aerosolized particles. Individuals can transmit SARS-CoV-2 to others before they have symptoms. Undetected cases play a major role in transmission, and most cases are not reported. Identifying the contribution of asymptomatic or pre-symptomatic transmission is important for implementing control measures. Additionally, the relative contributions of different infection sources – fomites, droplets, aerosols, and potentially feces – are unknown.</p>	
Host Range – How many species does it infect? Can it transfer from species to species?	5
<p>SARS-CoV-2 is closely related to other coronaviruses circulating in bats in Southeast Asia. Previous coronaviruses have passed through an intermediate mammal host before infecting humans, but the identity of the SARS-CoV-2 intermediate host is unknown. SARS-CoV-2 uses the same receptor for cell entry as the SARS-CoV-1 coronavirus that circulated in 2002/2003. To date, ferrets, mink, hamsters, cats, dogs, and primates have been shown to be susceptible to SARS-CoV-2 infection. It is unknown whether these animals can transmit infection to humans. Several animal models have been developed to recreate human-like illness, though to date they have been infected with high dose exposures. Lower dose studies may better replicate human disease acquisition.</p>	
Incubation Period – How long after infection do symptoms appear? Are people infectious during this time?.....	6
<p>The majority of individuals develop symptoms within 14 days of exposure. For most people, it takes at least 2 days to develop symptoms, and on average symptoms develop 5 days after exposure. Incubating individuals can transmit disease for several days before symptom onset. Some individuals never develop symptoms but can still transmit disease. The incubation period is well-characterized. Patients may be infectious, however, for days before symptoms develop.</p>	
Clinical Presentation – What are the signs and symptoms of an infected person?	7
<p>Many COVID-19 cases are asymptomatic. Most symptomatic cases are mild, but severe disease can be found in any age group. Older individuals and those with underlying medical conditions are at higher risk of serious illness and death. The case fatality rate varies substantially by patient age and underlying comorbidities. Evidence suggests that African Americans are at elevated risk of severe symptoms. Additional data on vulnerable subpopulations is needed. Children of all ages are susceptible to COVID-19,⁹⁴ though generally show milder^{65,191} or no symptoms. The true case fatality rate is unknown, as the exact number of cases is uncertain. Testing priorities and case definitions vary by location. The proportion of asymptomatic infections is not known.</p>	
Protective Immunity – How long does the immune response provide protection from reinfection?	8
<p>Infected patients show productive immune responses, however more data is needed. Currently, there is no evidence that recovered patients can be reinfected with SARS-CoV-2. Understanding the duration of protective immunity is limited by small sample sizes. Animal models are plausible surrogates. Additional research to quantify the risk of reinfection after weeks, months, and years is needed.</p>	
Clinical Diagnosis – Are there tools to diagnose infected individuals? When during infection are they effective?	9
<p>Diagnosis relies on identifying the genetic signature of the virus in patient nose, throat, or sputum samples. These tests are relatively accurate. Confirmed cases are still underreported. Validated serological (antibody) assays are being developed to help determine who has been exposed to SARS-CoV-2. Serological evidence of exposure does not indicate immunity.</p>	

In general, PCR tests appear to be sensitive and specific, though confirmation of symptoms via chest CT is recommended. The sensitivity and specificity of serological testing methods is variable, and additional work needs to be done to determine factors that affect test accuracy.

Medical Treatments – Are there effective treatments?.....10

Treatment for COVID-19 is primarily supportive care including ventilation if necessary.^{120, 200} Numerous clinical trials are ongoing, but results are preliminary.^{76, 30}

[Remdesivir shows promise for reducing symptom duration in humans.](#)²¹⁹

[Hydroxychloroquine is associated with elevated risk of cardiac arrhythmias and provides limited to no clinical benefit at this point in time.](#)

Other pharmaceutical interventions are being investigated.

In general, the efficacy of various therapeutic options for COVID-19 is unknown, though clinical trial results are beginning to be released.

Vaccines – Are there effective vaccines?.....11

Work is ongoing to develop a SARS-CoV-2 vaccine in human and animal trials. No preliminary results are available.

Phase 2 Trials (initial testing for efficacy, continued testing for safety):

No preliminary vaccine results for humans have been released.

Non-pharmaceutical Interventions – Are public health control measures effective at reducing spread?.....12

Broad-scale control measures such as stay-at-home orders are effective at reducing movement, and modeling shows evidence that they reduce transmission.

The effect of relaxing control measures is unknown, and research is needed to help plan for easing of restrictions.

As different US states have implemented differing control measures at various times, a comprehensive analysis of social distancing efficacy has not yet been conducted.

Environmental Stability – How long does the agent live in the environment?.....13

SARS-CoV-2 can persist on surfaces for at least 3 days and on the surface of a surgical mask for up to 7 days depending on conditions. If aerosolized intentionally, SARS-CoV-2 is stable for at least several hours. The seasonality of COVID-19 transmission is unknown.

Additional testing on SARS-CoV-2, as opposed to surrogate viruses, is needed to support initial estimates of stability.

Decontamination – What are effective methods to kill the agent in the environment?14

Soap and water, as well as common alcohol and chlorine-based cleaners, hand sanitizers, and disinfectants are effective at inactivating SARS-CoV-2 on hands and surfaces.

Methods for decontaminating N95 masks have been approved by the FDA under an Emergency Use Authorization (EUA).

Additional decontamination studies, particularly with regard to PPE and other items in short supply, are needed.

PPE – What PPE is effective, and who should be using it?15

The effectiveness of PPE for SARS-CoV-2 is currently unknown, and data from other related coronaviruses are used for guidance. Healthcare workers are at high risk of acquiring COVID-19, even with recommended PPE.

Most PPE recommendations have not been made on SARS-CoV-2 data, and comparative efficacy of different PPE for different tasks (e.g., intubation) is unknown. Identification of efficacious PPE for healthcare workers is critical due to their high rates of infection.

Forensics – Natural vs intentional use? Tests to be used for attribution.16

All current evidence supports the natural emergence of SARS-CoV-2 via a bat and possible intermediate mammal species.

Identifying the intermediate species between bats and humans would aid in reducing potential spillover from a natural source. Wide sampling of bats, other wild animals, and humans is needed to address the origin of SARS-CoV-2.

Genomics – How does the disease agent compare to previous strains?17

Current evidence suggests that SARS-CoV-2 accumulates substitutions and mutations at a similar rate as other coronaviruses. Mutations and deletions in specific portions of the SARS-CoV-2 genome have not been linked to any changes in transmission or disease severity, though modeling work is attempting to identify possible changes.


Research linking genetic changes to differences in phenotype (e.g., transmissibility, virulence, progression in patients) is needed.

SARS-CoV-2 (COVID-19)	Infectious Dose – How much agent will make a healthy individual ill?
<p>What do we know?</p>	<p>The human infectious dose of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is unknown by all exposure routes. SARS-CoV-2 is the cause of coronavirus disease 19 (COVID-19). <i>Work using SARS-CoV-2</i></p> <ul style="list-style-type: none"> • A total dose of approximately 700,000 plaque-forming units (PFU) of the novel coronavirus SARS-CoV-2 infected cynomolgus macaques via combination intranasal and intratracheal exposure (10^6 TCID₅₀ total dose).²⁵² Macaques did not exhibit clinical symptoms, but virus was shed from the nose and throat.²⁵² • Rhesus macaques are effectively infected with SARS-CoV-2 via the ocular conjunctival and intratracheal route at a dose of approximately 700,000 PFU (10^6 TCID₅₀).⁹² • Rhesus macaques infected with 2,600,000 TCID₅₀ of SARS-CoV-2 by the intranasal, intratracheal, oral and ocular routes combined recapitulate moderate disease observed in the majority of human cases.²¹⁴ • Rhesus and cynomolgus macaques showed clinical infections at doses of 4.75×10^6 PFU (SARS-CoV-2 delivered through several routes), while common marmosets developed mild infections when exposed to 1.0×10^6 PFU intranasally.¹⁹⁰ • Ferrets infected with 316,000 TCID₅₀¹⁴⁸ or 600,000 TCID₅₀²⁴⁶ of SARS-CoV-2 by the intranasal route show similar symptoms to human disease.^{148, 246} Uninfected ferrets in direct contact with infected ferrets test positive and show disease as early as 2 days post-contact.¹⁴⁸ In one study, direct contact was required to transfer infection between ferrets,¹⁴⁸ however, transmission without direct contact was found in another study.²⁴⁶ • Syrian Golden Hamsters infected with 100,000 PFU via the intranasal route closely resemble human respiratory infection. Uninfected hamsters in close contact with infected hamsters show symptoms within 4 days of exposure.⁶² • Domestic cats exposed to 100,000 PFU of SARS-CoV-2 via the intranasal route developed severe pathological symptoms including lesions in the nose, throat, and lungs.²⁶⁶ Younger cats exhibited more severe symptoms than older cats.²⁶⁶ <p>The correlation between the infectious dose and symptom severity is unknown.</p> <ul style="list-style-type: none"> • It has been suggested that higher viral loads at hospitalization correspond to more severe clinical outcomes,^{185, 280} though asymptomatic individuals also show viral loads comparable to symptomatic individuals.^{19, 338} <p><i>Related Coronaviruses</i></p> <ul style="list-style-type: none"> • The infectious dose for severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1) in mice is estimated to be between 67-540 PFU (average 240 PFU, intranasal route).^{89, 91} • Genetically modified mice exposed intranasally to doses of Middle East respiratory syndrome coronavirus (MERS-CoV) between 100 and 500,000 PFU show signs of infection. Infection with higher doses result in severe syndromes.^{12, 77, 171, 330}
<p>What do we need to know?</p>	<p>Identifying the infectious dose for humans by the various routes through which we become infected is critical to the effective development of computational models to predict risk, develop diagnostics and countermeasures, and effective decontamination strategies. Animal studies are a plausible surrogate.</p> <ul style="list-style-type: none"> • Human infectious dose by aerosol route • Human infectious dose by surface contact (fomite) • Human infectious dose by fecal-oral route

SARS-CoV-2 (COVID-19)	Transmissibility – How does it spread from one host to another? How easily is it spread?
<p>What do we know?</p>	<p>SARS-CoV-2 is passed easily between humans, likely through close contact with relatively large droplets and possibly through smaller aerosolized particles.</p> <ul style="list-style-type: none"> • Pandemic COVID-19 has caused 3,618,325 infections and 253,381 deaths¹⁴¹ in at least 187 countries and territories (as of 5/5/2020).^{54, 262, 305} • In the US there are 1,181,885 confirmed SARS-CoV-2 cases across all 50 US states, with 69,079 deaths (as of 5/5/2020).¹⁴¹ • Initial high-quality estimates of human transmissibility (R_0) range from 2.2 to 3.1.^{197, 228, 249, 313, 329} • SARS-CoV-2 is believed to spread through close contact and droplet transmission,⁵⁸ with fomite transmission likely¹⁴³ and close-contact aerosol transmission plausible^{42, 119} but unconfirmed.³⁰⁴ • SARS-CoV-2 replicates in the upper respiratory tract, and infectious virus is detectable in throat and lung tissue for at least 8 days.³⁰⁸ SARS-CoV-2 also infects human gut cell lines.¹⁶⁰ • Contamination of patient rooms with aerosolized SARS-CoV-2 in the human respirable range (0.25-2.5 μm) indicates the potential for airborne transmission.¹⁸⁴ To date infectious virus has not been isolated from aerosol samples.²⁵⁹ Contamination may be worse in intensive care rooms, with viral RNA detected up to 4 meters from patient beds.¹²¹ • Limited evidence suggests that SARS-CoV-2 may be spread by conversation and exhalation in the absence of cough, however more work is needed.^{9, 170, 259} A preliminary study in China detailing a restaurant-associated outbreak supports aerosol transmission, though confirmation is needed.¹⁷⁶ • Experimentally infected ferrets were able to transmit SARS-CoV-2 to other ferrets by both direct contact (another ferret in same enclosure) as well as through the air (ferrets in an adjacent enclosure, separated by 10 cm).²⁴⁶ • Evidence suggests that SARS-CoV-2 is not transmitted to infants during birth.^{67, 70, 72, 261, 322, 324} <p>Individuals can transmit SARS-CoV-2 to others before they have symptoms.</p> <ul style="list-style-type: none"> • Pre-symptomatic^{269, 332} or asymptomatic^{25, 133, 194} patients can transmit SARS-CoV-2. At least 12%⁹⁶ of all cases are estimated to be due to asymptomatic transmission, and between 23%¹⁸² and 44%¹²³ of infections may be caused by pre-symptomatic transmission. Asymptomatic and pre-symptomatic individuals have similar amounts of virus in the nose and throat compared to symptomatic patients.^{19, 338} Infected patients transmitted infection to more close contacts in the early stages of their infection, before symptoms began and within 5 days of symptom onset, compared to later stages of infection.⁷¹ • Individuals may be infectious for 1-3 days prior to symptom onset,²⁹⁵ and culturable virus has been found in individuals up to 6 days prior to symptom onset.¹⁹ • Severe cases are more likely to transmit disease, and most new infections are within households of infected patients.¹⁹² In China, it is estimated that infected individuals transmit COVID-19 to between 11.2%³⁴ and 16.3%¹⁷⁴ of household contacts, though even more may lack symptoms.¹⁹⁴ <p>Undetected cases play a major role in transmission, and most cases are not reported.</p> <ul style="list-style-type: none"> • Models suggest up to 86% of early COVID-19 cases in China were undetected, and these infections were the source for 79% of reported cases.¹⁷³ • Models estimate that the true number of cases may be approximately 11 times greater than the reported number of cases in the UK,³²³ and 5 to 10 times greater than the reported number of cases in the US.^{144, 256} Preliminary estimates of the case reporting rate vary widely among countries, from roughly 1 reported case for every 3 actual cases (in Germany), to 1 in 149 (in China).¹⁵²
<p>What do we need to know?</p>	<p>Identifying the contribution of asymptomatic or pre-symptomatic transmission is important for implementing control measures. Additionally, the relative contributions of different infection sources – fomites, droplets, aerosols, and potentially feces – are unknown.</p> <ul style="list-style-type: none"> • Capability of SARS-CoV-2 to be transmitted by contact with fomites (phones, doorknobs, surfaces, clothing, etc.) – see also Experimental Stability • Updated person to person transmission rates (e.g., R_0) as control measures take effect. • Can individuals become re-infected with SARS-CoV-2? • Is the R_0 estimate higher in healthcare or long-term care facilities? • When will infections peak in various cities and countries? • Are small-diameter (<5 μm) aerosol exposures capable of infecting humans? • How far do infectious aerosols (small-diameter, <5 μm) travel?

SARS-CoV-2 (COVID-19)	Host Range – How many species does it infect? Can it transfer from species to species?
<p>What do we know?</p>	<p>SARS-CoV-2 is closely related to other coronaviruses circulating in bats in Southeast Asia. Previous coronaviruses have passed through an intermediate mammal host before infecting humans, but the identity of the SARS-CoV-2 intermediate host is unknown.</p> <ul style="list-style-type: none"> • Early genomic analysis indicates similarity to SARS-CoV-1,³³⁶ with a suggested bat origin.^{79, 336} • Positive samples from the South China Seafood Market strongly suggests a wildlife source,⁶⁰ though it is possible that the virus was circulating in humans before the disease was associated with the seafood market.^{29, 80, 317, 325} • Analysis of SARS-CoV-2 genomes suggests that a non-bat intermediate species is responsible for the beginning of the outbreak.²⁵¹ The identity of the intermediate host remains unknown.^{175, 179-180} • Viruses similar to SARS-CoV-2 were present in pangolin samples collected several years ago.¹⁵⁹ <p>SARS-CoV-2 uses the same receptor for cell entry as the SARS-CoV-1 coronavirus that circulated in 2002/2003.</p> <ul style="list-style-type: none"> • Experiments show that SARS-CoV-2 Spike (S) receptor-binding domain binds the human cell receptor (ACE2) stronger than SARS-CoV-1,³¹¹ potentially explaining its high transmissibility. The same work suggests that differences between SARS-CoV-2 and SARS-CoV-1 Spike proteins may limit the therapeutic ability of SARS antibody treatments.³¹¹ • Modeling of SARS-CoV-2 Spike and ACE2 proteins suggests that SARS-CoV-2 can bind and infect human, bat, civet, monkey and swine cells.²⁸⁶ <i>In vitro</i> experiments suggest a broad host range for SARS-CoV-2, with more than 44 potential animal hosts, based on viral binding to species-specific ACE2 orthologs.¹⁸³ The host range is predicted to be limited primarily to mammals. Host range predictions based on structural modeling, however, are difficult,¹¹¹ and additional animal studies to better define the host range of SARS-CoV-2 are needed. • Genetic and protein analysis of primates suggests that African and Asian primates are likely more susceptible to SARS-CoV-2, while South and Central American primates are likely less susceptible.²⁰⁷ Confirming the SARS-CoV-2 host range is important for identifying potential animal reservoirs. • Changes in proteolytic cleavage of the Spike protein can also affect cell entry and animal host range, in addition to receptor binding.²⁰⁸ <p>To date, ferrets, mink, hamsters, cats and primates have been shown to be susceptible to SARS-CoV-2 infection. It is unknown whether these animals can transmit infection to humans.</p> <ul style="list-style-type: none"> • Animal model studies suggest that Golden Syrian hamsters, primates, and ferrets may be susceptible to infection.^{62, 148} <i>In the Netherlands, farmed mink developed breathing and gastrointestinal issues, which was diagnosed as SARS-CoV-2 infection.</i>² • Domestic cats are susceptible to infection with SARS-CoV-2 (100,000 PFU via the intranasal route), and can transmit the virus to other cats via droplet or short-distance aerosol.²⁶⁶ Dogs exposed to SARS-CoV-2 produced anti-SARS-CoV-2 antibodies but exhibited no clinical symptoms.²⁶⁶ • Wild cats (tigers)²⁹⁴ can be infected with SARS-CoV-2, although their ability to spread to humans is unknown.^{198, 328} Two cases have been confirmed of pet domestic cats infected with SARS-CoV-2.⁵³ • Ducks, chickens, and pigs remained uninfected after experimental SARS-CoV-2 (30,000 CFU for ducks and chickens, 100,000 PFU for pigs, all via intranasal route).²⁶⁶ There is currently no evidence that SARS-CoV-2 infects livestock,¹³⁸ <i>though modeling suggests sheep, cows, pigs, and goats may be susceptible to infection by SARS-CoV-2.</i>¹⁵⁸
<p>What do we need to know?</p>	<p>Several animal models have been developed to recreate human-like illness, though to date they have been infected with high dose exposures. Lower dose studies may better replicate human disease acquisition.</p> <ul style="list-style-type: none"> • What is the intermediate host(s)? • What are the mutations in SARS-CoV-2 that allowed human infection and transmission? • What other animals can SARS-CoV-2 infect (e.g., potential wildlife reservoirs)? • Can infected animals transmit to humans (e.g., pet cats to humans)? • <i>Can SARS-CoV-2 circulate in animal reservoir populations, potentially leading to future spillover events?</i>

SARS-CoV-2 (COVID-19)	Incubation Period – How long after infection do symptoms appear? Are people infectious during this time?
<p>What do we know?</p>	<p>The majority of individuals develop symptoms within 14 days of exposure. For most people, it takes at least 2 days to develop symptoms, and on average symptoms develop 5 days after exposure. Incubating individuals can transmit disease for several days before symptom onset. Some individuals never develop symptoms but can still transmit disease.</p> <ul style="list-style-type: none"> • The best current estimate of the COVID-19 incubation period is 5.1 days, with 99% of individuals exhibiting symptoms within 14 days of exposure.¹⁶⁵ Fewer than 2.5% of infected individuals show symptoms sooner than 2 days after exposure.¹⁶⁵ • Individuals can test positive for COVID-19 even if they lack clinical symptoms.^{25, 61, 120, 276, 332} • Individuals can be infectious while asymptomatic,^{58, 254, 276, 332} and asymptomatic individuals can have similar amounts of virus in their nose and throat as symptomatic individuals.³³⁸ • Peak infectiousness may be during the incubation period, one day before symptoms develop.¹²³ Infectious virus has been cultured in patients up to 6 days before the development of symptoms.¹⁹ • Infectious period is unknown, but possibly up to 10-14 days.^{8, 173, 262} • Asymptomatic individuals are estimated to be infectious for a median of 9.5 days.¹³¹ • On average, there are approximately 4⁹⁶ to 7.5¹⁷² days between symptom onset in successive cases of a single transmission chain (i.e., the serial interval). Based on data from 339 transmission chains in China, the mean serial interval is 5.29 days.⁹⁵ • Most hospitalized individuals are admitted within 8-14 days of symptom onset.³³⁴
<p>What do we need to know?</p>	<p>The incubation period is well-characterized. Patients may be infectious, however, for days before symptoms develop.</p> <ul style="list-style-type: none"> • What is the average infectious period during which individuals can transmit the disease?



SARS-CoV-2 (COVID-19)	Clinical Presentation – What are the signs and symptoms of an infected person?
<p>What do we know?</p>	<p>Many COVID-19 cases are asymptomatic. Most symptomatic cases are mild, but severe disease can be found in any age group. Older individuals and those with underlying medical conditions are at higher risk of serious illness and death.</p> <ul style="list-style-type: none"> • Estimates of the proportion of individuals with asymptomatic infections vary widely (e.g., 43%,¹⁶⁶ 60%,²⁷⁰ 87%,²⁷⁴ 95%,²⁶⁸ 100%²⁵³ in broadly-sampled populations). Some individuals who are asymptomatic at testing will later develop symptoms.¹⁹ Widespread, repeated testing is needed. • The majority of symptomatic COVID-19 cases are mild (81%, n=44,000 cases).²⁷⁶ Initial COVID-19 symptoms include fever (87.9% overall, but only 44-52% present with fever initially),^{17, 120} cough (67.7%),¹²⁰ fatigue, shortness of breath, headache, and reduced lymphocyte count.^{59, 64, 132} Chills, muscle pain, headache, sore throat, and loss of taste or smell³²¹ are also possible COVID-19 symptoms.⁵⁹ The prevalence of GI symptoms varies.¹¹³ • Complications include acute respiratory distress (ARDS, 17-29% of hospitalized patients, leading to death in 4-15% of cases),^{69, 132, 288} pneumonia,²²⁵ cardiac injury (20%),²⁶⁷ secondary infection, kidney damage,²⁷¹ arrhythmia, sepsis, and shock.^{120, 132, 288, 334} Most deaths are caused by respiratory failure or respiratory failure combined with myocardial (heart) damage.²⁵⁵ • Approximately 15% of hospitalized patients are classified as severe,^{120, 276} and approximately 5% of patients are admitted to the ICU.^{120, 276} Patient deterioration can be rapid.¹¹⁸ Mortality rates of patients requiring mechanical ventilation vary substantially: approximately 65% in the UK,¹³⁷ 30% in the state of Georgia,²¹ and 24.5% in New York City (though many cases had not yet resolved).²⁴⁷ • A number of immunological indicators may help differentiate between severe and non-severe cases.^{22, 99, 122, 134, 233, 273} • Ocular symptoms have been seen in severe COVID-19 cases,³¹⁵ and blood clots appear more common in COVID-19 patients in intensive care than the general population.¹⁵⁰ Skin lesions may be symptoms of COVID-19, though additional studies are needed.³⁹ <p>The case fatality rate varies substantially by patient age and underlying comorbidities.</p> <ul style="list-style-type: none"> • The CFR depends on comorbidities. Cardiovascular disease, hypertension, diabetes, and respiratory conditions all increase the CFR.^{206, 276, 334} Almost 50% of hospitalized patients in the US have either hypertension or obesity.¹¹³ This is higher than rates in other countries and increases mortality.^{18, 226} • The CFR increases with age. Individuals >60 are at higher risk of death, and the CFR for individuals >85 is between 10 and 27%.^{276, 334} In the US, 34% of hospitalizations have been individuals younger than 44 years old.⁶ • In a small case study, men were found to exhibit more severe symptoms and die at higher rates than women.¹⁴² The effect of comorbidities on the likelihood of severe symptoms is also higher for men than for women.²⁰⁹ <p>Evidence suggests that African Americans are at elevated risk of severe symptoms. Additional data on vulnerable subpopulations is needed.</p> <ul style="list-style-type: none"> • African Americans are disproportionately represented in hospitalized populations (33% of hospitalized patients, only 18% of the base study population),¹¹³ despite having similar rates of several underlying conditions as other groups.¹¹⁷ • Pregnant women appear to develop severe symptoms at the same rate as the general population.⁶⁸ <p>Children of all ages are susceptible to COVID-19,⁹⁴ though generally show milder^{65, 191} or no symptoms.</p> <ul style="list-style-type: none"> • Between 21-28% of children may be asymptomatic.^{229, 236} A detailed study of 100 children with COVID-19 found that 21% were asymptomatic, 58% developed mild illness, 19% had moderate illness, 1% had severe illness, and 1% developed critical illness.²²⁹ • Severe symptoms in children are possible,¹⁸¹ and infant deaths have been recorded.^{44, 191}
<p>What do we need to know?</p>	<p>The true case fatality rate is unknown, as the exact number of cases is uncertain. Testing priorities and case definitions vary by location. The proportion of asymptomatic infections is not known.</p> <ul style="list-style-type: none"> • How long does it take for infected individuals to recover outside of a healthcare setting? • Are pregnant women at greater risk of complications during labor?¹⁷⁸ • What proportion of infected individuals are asymptomatic? Does this vary by age, location, or comorbidities? • Studies that test entire populations repeatedly over time and link those tests to the presence or absence of symptoms are necessary.

SARS-CoV-2 (COVID-19)	Protective Immunity – How long does the immune response provide protection from reinfection?
<p>What do we know?</p>	<p>Infected patients show productive immune responses, however more data is needed.</p> <ul style="list-style-type: none"> • In a limited study (n=9), hospitalized patients shed high levels of infectious virus for 7 days via the nasal-pharyngeal route. 50% of patients produced antibodies within 7 days, and all patients produced antibodies by 14 days. Antibody production did not correlate with lower viral load.³⁰⁸ • In a larger study (n=175), most patients developed neutralizing antibodies within 10-15 days after disease onset. Elderly patients had significantly higher neutralizing antibody titers than younger patients.³¹² <i>In a separate study, elderly patients also showed higher viral loads than younger patients.</i>²⁸⁰ • In a study of 285 COVID-19 patients, 100% developed antiviral immunoglobulin-G within 19 days of symptom onset.¹⁸⁶ The neutralizing ability of these antibodies was not tested.¹⁸⁶ In a smaller in vitro study (n=23 patients), levels of antibodies (immunoglobulins M and G) were positively correlated with SARS-CoV-2 neutralizing ability.²⁸⁰ • In a small series of 26 mild COVID-19 cases, researchers found prolonged persistence of SARS-CoV-2 antibodies and SARS-CoV-2 RNA for up to 50 days. Additionally, one patient cleared SARS-CoV-2 without developing a significant antibody response.²⁸⁷ • Based on one patient, a productive immune response is generated and sustained for at least 7 days.²⁷⁷ Previous studies on coronavirus immunity suggest that neutralizing antibodies may wane after several years.^{46, 314} More data are needed. • A small subset of COVID-19 patients in China (8%) did not develop a serological response to infection, though the potential for reinfection in these patients is unknown.³¹² Similarly, between 16.7% (for IgG) and 51.7% (for IgM) of patients in a separate study did not exhibit any immune response, in terms of production of those two types of antibodies.²⁷⁵ • In a study of 221 COVID-19 patients, levels of two types of antibodies (IgM and IgG) were not associated with the severity of symptoms.¹³⁰ However, in a smaller study, patients with severe disease showed stronger antibody responses than those with non-severe symptoms.²⁸⁰ <p>Currently, there is no evidence that recovered patients can be reinfected with SARS-CoV-2.</p> <ul style="list-style-type: none"> • Experimentally infected macaques were not capable of being reinfected after their primary infection resolved.²⁶ • According to the WHO, there is no evidence of re-infection with SARS-CoV-2 after recovery.¹⁶⁴ • Patients can test positive via PCR for up to 37 days after symptoms appear,³³⁴ and after recovery and hospital discharge.¹⁶¹ The ability of these individuals to infect others is unknown. <p>Similarly, there is no evidence that recovered patients are protected against reinfection with SARS-CoV-2.³⁰¹</p> <ul style="list-style-type: none"> • Additional research is required before any conclusions can be drawn about the duration of protective immunity after SARS-CoV-2 infection.¹³
<p>What do we need to know?</p>	<p>Understanding the duration of protective immunity is limited by small sample sizes. Animal models are plausible surrogates. Additional research to quantify the risk of reinfection after weeks, months, and years is needed.</p> <ul style="list-style-type: none"> • How long does the immune response last? • Is there evidence of waning immunity? • Can humans become reinfected? • Are patients who test positive weeks after discharge from hospital capable of transmitting infection? • How does the patient immune response vary by age or disease severity? • How do different components of the immune response contribute to long-term protection?

SARS-CoV-2 (COVID-19)	Clinical Diagnosis – Are there tools to diagnose infected individuals? When during infection are they effective?
<p>What do we know?</p>	<p>Diagnosis relies on identifying the genetic signature of the virus in patient nose, throat, or sputum samples. These tests are relatively accurate. Confirmed cases are still underreported.</p> <ul style="list-style-type: none"> • The US CDC has expanded testing criteria to include symptomatic patients at clinician discretion.²⁸ • PCR protocols and primers have been widely shared internationally,^{51, 82, 172, 265, 300, 306} PCR-based diagnostic assays are unable to differentiate between active and inactive virus. • Broad testing in Iceland suggests that approximately 50% of those who tested positive were asymptomatic at the time of testing.^{20, 212} • A combination of pharyngeal (throat) RT-PCR and chest tomography is the most effective diagnostic criteria (correctly diagnoses 91.9% of infections).²⁴⁴ A single throat swab detects 78.2% of infections, and duplicate tests identify 86.2% of infections.²⁴⁴ • PCR tests using saliva were better able to detect SARS-CoV-2 RNA than those using nasopharyngeal swabs, and may be useful for self, at-home sampling.³¹⁶ Additional validation is needed. • Nasal and pharyngeal swabs may be less effective as diagnostic specimens than sputum and bronchoalveolar lavage fluid,²⁹⁰ although evidence is mixed.³⁰⁸ Combination RT-PCR and serology (antibody) testing may increase the ability to diagnose patients with mild symptoms, or identify patients at higher risk of severe disease.³³¹ • RT-PCR tests can identify asymptomatic cases; SARS-CoV-2 infection was identified in 2/114 individuals cleared by clinical assessment.¹²⁷ • The FDA released an Emergency Use Authorization enabling laboratories to develop and use tests in-house for patient diagnosis.¹⁰⁵ • Updated tests from the US CDC are available to states.^{51, 58} • Multiple rapid or real-time test kits have been produced by universities and industry, including the Wuhan Institute of Virology,⁸⁵ BGI,³³ Cepheid,²⁸⁵ Abbot,¹⁰³ and Mesa Biotech.³⁵ • The US CDC is developing serological tests to determine what proportion of the population has been exposed to SARS-CoV-2.¹⁴⁶ A rapid antibody test by Cellex is now authorized by the FDA.^{126, 297} • Home tests are being developed; however none are FDA approved, nor are they useable as a diagnostic.^{215-216, 227} • Artificial intelligence algorithms were able to improve the ability of radiologists to distinguish COVID-19 pneumonia from non-COVID-19 pneumonia on chest CT scans.²⁴ <p>Validated serological (antibody) assays are being developed to help determine who has been exposed to SARS-CoV-2. Serological evidence of exposure does not indicate immunity.</p> <ul style="list-style-type: none"> • Researchers found high specificity in a number of enzyme-linked immunosorbent assays (ELISA), though sample sizes for SARS-CoV-2 patients were small.²²⁰ Additional research has shown high variability in the ability of tests (ELISA and lateral flow assays) by different manufacturers to accurately detect positive and negative cases (sensitivity and specificity, respectively).^{163, 298} Lateral flow assays may be less reliable than ELISA.¹⁰ • In one German town, serological testing has been used to identify the percent of the population already exposed to SARS-CoV-2 (14%), which can assist in public health response planning.²⁴² • Preliminary serological studies in Santa Clara and Los Angeles, California, estimated that 2.5-4.1% of the population has already been exposed to SARS-CoV-2 since the first confirmed cases in January,^{31, 199} which is between 28 and 85 times greater than official reports. There are issues, however, with non-random study populations,³¹ as well as false positive rates of the diagnostic tests themselves.¹⁹⁹ The false positive rate of the diagnostic assay used may account for a substantial portion of the reported infections,³¹ particularly if the true proportion of positive patients is low. • In New York, initial serological testing indicates that 13.9% of the population has been exposed to COVID-19, approximately 10 times greater than the number of reported cases.³ This is in line with other underreporting estimates in the US.^{144, 256}
<p>What do we need to know?</p>	<p>In general, PCR tests appear to be sensitive and specific, though confirmation of symptoms via chest CT is recommended. The sensitivity and specificity of serological testing methods is variable, and additional work needs to be done to determine factors that affect test accuracy.</p> <ul style="list-style-type: none"> • How accurate are clinical diagnoses compared to genetic tests? • How effective are different swab specimens as diagnostic samples? • How many serological tests need to be done to obtain an accurate picture of underlying exposure?

SARS-CoV-2 (COVID-19)	Medical Treatments – Are there effective treatments?
<p>What do we know?</p>	<p>Treatment for COVID-19 is primarily supportive care including ventilation if necessary.^{120, 200} Numerous clinical trials are ongoing, but results are preliminary.^{30, 76}</p> <ul style="list-style-type: none"> • Two WHO-backed clinical trials (Solidarity and Discovery)¹⁵⁵ include remdesivir, hydroxychloroquine and chloroquine, ritonavir/lopinavir, and ritonavir/lopinavir and interferon-beta.¹⁵⁵ <p>Remdesivir shows promise for reducing symptom duration in humans.²¹⁹</p> <ul style="list-style-type: none"> • Remdesivir can reduce the duration of symptoms in infected individuals, from 15 days to 11 days on average (compared to controls).²¹⁹ There is a possibility remdesivir may reduce mortality rates, though the result was not statistically significant.²¹⁹ In this trial, individuals with mild symptoms were excluded.²¹⁹ Remdesivir has received an Emergency Use Authorization from the FDA.²¹⁷ • In a clinical trial of severe COVID-19 patients, the effects of remdesivir were inconclusive due to a limitation in the study sample size.²⁹² For available patients, remdesivir did not reduce the time to recovery overall, but did show a tendency to reduce symptom duration for patients given the drug early.²⁹² This trial ended early, reducing its statistical power.²⁹² <p>Hydroxychloroquine is associated with elevated risk of cardiac arrhythmias and provides limited to no clinical benefit at this point in time.</p> <ul style="list-style-type: none"> • A study of 181 COVID-19 patients in France found that hydroxychloroquine (600 mg/day) did not reduce the need for intensive care or mortality compared to a control group.¹⁹⁶ Additionally, 9% of the treatment group suffered cardiac arrhythmias that necessitated premature withdrawal of treatment.¹⁹⁶ A study of US veterans treated with hydroxychloroquine alone or in combination with azithromycin found no benefit from either treatment compared to a control group.¹⁹⁵ The same study identified an increased risk of mortality in patients treated with hydroxychloroquine alone.¹⁹⁵ • A US cohort study of 90 patients given hydroxychloroquine for COVID-19 infection (with or without azithromycin) found higher potential for cardiac arrhythmias due to corrected QT (QTc) prolongation.²¹⁰ In France, 40 ICU patients were treated with hydroxychloroquine and most showed increases in QTc interval, with the effects more pronounced for patients also given azithromycin.³² The results from two ongoing clinical trials are needed to further evaluate safety and efficacy.³⁶ • Initial results purporting benefits of hydroxychloroquine and azithromycin¹¹⁵ have been called into question by other researchers¹³⁶ and the journal's publishing society.¹³⁹ <p>Other pharmaceutical interventions are being investigated.</p> <ul style="list-style-type: none"> • Limited, preliminary evidence from clinical trials supports the efficacy of favipiravir⁶⁶ (which has been approved to treat COVID-19 in China)¹ and intravenous immunoglobulin.⁴⁸ • Limited, preliminary research found no efficacy from combination ritonavir and lopinavir.⁴⁷ • Early results from a randomized clinical trial found that high doses (600 mg, twice per day) of chloroquine diphosphate were associated with toxicity and lethality in patients with severe COVID-19.³⁷ The trial did not have a large enough sample size to assess chloroquine treatment efficacy.³⁷ • A small (n=21) retrospective study found benefits of tocilizumab in severe COVID-19 patients, though the study lacked a control group.³¹⁸ Potential benefits of immunosuppressants⁷ should be weighed against the possibility of negative effects.²³⁹ • Clinical trials are underway with famotidine³⁸ (a heartburn reliever) and mesenchymal stromal cells (cells derived from convalescent patient bone marrow)¹²⁹ to treat ARDS. • Heparin is being used to mitigate risks of pulmonary embolism, potentially caused by COVID-19-associated hypercoagulability.⁹⁹ • Passive antibody therapy (convalescent serum)⁴⁹ is being given to patients (FDA Investigational New Drug approval).¹⁰⁴ In a small trial (5 patients),²⁶³ convalescent sera administration was followed by clinical improvement.²⁶³ Large efforts are underway to broaden and enhance serum therapies.²⁶⁴ • Corticosteroids are commonly given to COVID-19 patients³³⁴ at risk of ARDS,³¹⁹ but their use is not recommended by the US CDC.⁵⁵ A small (n=115 patients) trial in China found no benefit of corticosteroids in terms of admission to the ICU or death,²⁸⁹ though a small study suggested that methylprednisolone can reduce hospital stay time.²⁹¹
<p>What do we need to know?</p>	<p>In general, the efficacy of various therapeutic options for COVID-19 is unknown, though clinical trial results are beginning to be released.</p> <ul style="list-style-type: none"> • Are convalescent plasma treatments effective in humans or animals? • Do monoclonal antibodies exhibit any efficacy in human trials? • Are viral replicase inhibitors such as beta-D-N4-hydroxycytidine effective against SARS-CoV-2?²⁷

SARS-CoV-2 (COVID-19)	Vaccines – Are there effective vaccines?
<p>What do we know?</p>	<p>Work is ongoing to develop a SARS-CoV-2 vaccine in human and animal trials. No preliminary results are available.</p> <ul style="list-style-type: none"> Multiple entities are working to produce a SARS-CoV-2 vaccine,¹⁴ including HHS/NIH/NIAID,^{124, 169} CEPI, Moderna Therapeutics, Pfizer,¹⁰⁰ Gilead Sciences,^{4-5, 218} Sanofi,⁴⁰ and Johnson and Johnson.¹⁴⁵ Vaccine candidates undergoing clinical trial are listed below. <p><i>Phase 2 Trials (initial testing for efficacy, continued testing for safety):</i></p> <ul style="list-style-type: none"> China's CanSino is the first to complete Phase 1 safety trials of their adenovirus type5 vector based Sars-CoV-2 vaccine, Ad5-nCoV, and has advanced to Phase 2 human trials.¹⁷⁷ <p><i>Phase 1 Trials (initial testing for safety):</i></p> <ul style="list-style-type: none"> Sinovac Biotech has reported that their inactivated virus vaccine shows protective effects in rhesus macaques, particularly at high doses.¹¹² The vaccine is currently in phase 1 clinical trials.⁷⁸ Moderna has a Phase 1 trial underway based on its mRNA platform, mRNA-1273. Inovio had their IND approved by the FDA and have started their Phase 1 clinical trials on their DNA vaccine candidate INO-4800.²⁵⁷ Shenzhen Geno-Immune Medical Institute is testing its aAPC²⁰⁵ and lentiviral²⁰⁴ vaccines in Phase 1 clinical trials. BioNTech and Pfizer's BNT162 program is in Phase 1/2 clinical trial for four of its mRNA vaccine candidates.²³² University of Oxford's ChAdOx1 vaccine is in Phase 1 clinical trials. This vaccine is based on a chimpanzee adenovirus expressing SARS-CoV-2 proteins.²³¹ The Beijing Institute of Biological Products/Wuhan Institute of Biological Products have initiated a Phase I trial of their inactivated vaccine candidate.³⁰⁷ Symvivo Corporation has received approval for a Phase I trial with their oral bacTRL-Spike vaccine candidate.²⁰³ <p><i>Co-opting existing vaccines</i></p> <ul style="list-style-type: none"> Some efforts have begun to enroll healthcare workers in clinical trials to study the efficacy of the BCG (Bacillus Calmette-Guérin) vaccine for reducing symptom severity in COVID-19 patients.²⁰²
<p>What do we need to know?</p>	<p>No preliminary vaccine results for humans have been released.</p> <ul style="list-style-type: none"> Safety of candidate vaccines in humans and animals Efficacy of candidate vaccines in humans and animals Length of any vaccine-derived immunity Evidence for vaccine-derived enhancement (immunopotential)

SARS-CoV-2 (COVID-19)	Non-pharmaceutical Interventions – Are public health control measures effective at reducing spread?
<p>What do we know?</p>	<p>Broad-scale control measures such as stay-at-home orders are effective at reducing movement, and modeling shows evidence that they reduce transmission.</p> <ul style="list-style-type: none"> • Social distancing and other policies are estimated to have reduced COVID-19 spread by 44% in Hong Kong⁸⁴ and reduced spread throughout China^{151, 154, 157, 188} and Italy.¹¹⁴ Restrictive lockdowns in China are estimated to have reduced disease transmission within only a few days,³³⁷ in part, through reductions in an individual’s average number of contacts.³²⁶ • Modeling demonstrates that multifaceted restrictions and quarantines in China reduced the R_0 of SARS-CoV-2 from greater than 3 to less than 1 between January 23 and February 5.²²⁴ Additionally, movement restrictions and other control measures helped limit the amount of time where community transmission was possible (i.e., $R_0 > 1$).³²⁷ • Models indicate that a combination of school closures, work restrictions, and other measures are required to effectively limit transmission.¹⁰⁷ School closures alone appear insufficient.^{140, 157} • Non-pharmaceutical interventions in China did not reduce transmission equally across all groups; transmission rates in younger individuals, particularly infants, as well as hospital workers continued to increase even while overall transmission rates declined.²²⁴ • Anonymized cell phone location data indicate major reductions in mobility due to social distancing.¹⁰⁹ Mobility in major US cities declined after each public health intervention implemented.¹⁶² • Contact tracing reduces the amount of time infectious individuals can transmit disease in a population and increases the time between successive cases (the serial interval).³⁴ <p>The effect of relaxing control measures is unknown, and research is needed to help plan for easing of restrictions.</p> <ul style="list-style-type: none"> • Modeling indicates that COVID-19 is likely to become endemic in the US population, with regular, periodic outbreaks, and that additional social or physical distancing measures may be required for several years to keep cases below critical care capacity in absence of a vaccine or effective therapeutic.¹⁴⁹ Results depend critically on the duration of immunity after exposure.¹⁴⁹ • Modeling suggests that premature lifting of social distancing measures will substantially increase the number of local COVID-19 cases in Wuhan, China.²³⁴ Similarly, forecasts in the US estimate a resumption of exponential case growth if social distancing measures are relaxed.⁸⁶ • In the UK, modelers are assessing the efficacy of rolling interventions, whereby social distancing measures are put into place every few weeks to keep healthcare demand below a critical point.³²³ • A modeling study using Chinese data estimated the impact of relaxing social distancing measures after an initial reduction in disease transmission. Results suggest that if R_0 is allowed to rise above 1, tightening controls may not be enough to keep transmission low; rather, additional effort would be needed to drive R_0 below 1 again, suggesting that carefully balancing control measures to maintain R_0 below 1 would be more efficient than allowing R_0 to increase again in the first place.¹⁶⁷ • Robust contact tracing and case finding may be needed to control COVID-19 in the US, but would require additional staff and resources to conduct effectively.²⁹³ • A model suggests that reducing public contacts is more important for controlling spread than reducing private (e.g., in-home) contacts.²⁰¹ • The WHO has released guidelines on public health strategy, focusing on controlling transmission, ensuring public health capacity is robust, and engaging local communities.²⁹⁹ • Johns Hopkins released a report outlining how to re-open certain categories of activities (e.g., schools, restaurants, events) while reducing COVID-19 risk; the report also ranks certain activities by their contact intensity, number of contacts, and the potential to modify them to reduce risk.²⁵⁰
<p>What do we need to know?</p>	<p>As different US states have implemented differing control measures at various times, a comprehensive analysis of social distancing efficacy has not yet been conducted.</p> <ul style="list-style-type: none"> • How many cases in the US have been averted due to social distancing restrictions? • How long does it take for various non-pharmaceutical interventions to show effects? • What are effective surrogate measures of social distancing efficacy (e.g., reduction in travel, contact, traffic, etc.)? • What are plausible options for relaxing social distancing and other intervention measures without resulting in a resurgence of COVID-19 cases?

SARS-CoV-2 (COVID-19)	Environmental Stability – How long does the agent live in the environment?
<p>What do we know?</p>	<p>SARS-CoV-2 can persist on surfaces for at least 3 days and on the surface of a surgical mask for up to 7 days depending on conditions. If aerosolized intentionally, SARS-CoV-2 is stable for at least several hours. The seasonality of COVID-19 transmission is unknown.</p> <p><i>SARS-CoV-2 Data</i></p> <ul style="list-style-type: none"> • SARS-CoV-2 can persist on plastic and metal surfaces between 3 days (21-23°C, 40% RH)²⁸³ and 7 days (22°C, 65% RH). Infectious virus can be recovered from a surgical mask after 7 days (22°C, 65% RH).⁷⁴ • SARS-CoV-2 has an aerosol half-life of 2.7 hours (particles <5 µm, tested at 21-23°C and 65% RH).²⁸³ • SARS-CoV-2 is susceptible to heat treatment (70°C) but can persist for at least two weeks at refrigerated temperatures (4°C).^{74, 241} • SARS-CoV-2 genetic material (RNA) was detected in symptomatic and asymptomatic cruise ship passenger rooms up to 17 days after cabins were vacated. The infectiousness of this material is not known.²¹³ • In a preliminary study, SARS-CoV-2 stability was enhanced when present with bovine serum albumin, which is commonly used to represent sources of protein found in human sputum.²³⁰ • No strong evidence exists showing a reduction in transmission with seasonal increase in temperature and humidity.¹⁹³ Modeling suggests that even accounting for potential reductions in transmission due to weather and behavioral changes, public health interventions will still need to be in effect to limit COVID-19 transmission.²¹¹ <p><i>Surrogate Coronavirus data:</i></p> <ul style="list-style-type: none"> • Studies suggest that other coronaviruses can survive on non-porous surfaces up to 9-10 days (MHV, SARS-CoV),^{50, 63} and porous surfaces for up to 3-5 days (SARS-CoV)⁹⁸ in air conditioned environments (20-25°C, 40-50% RH). • Coronavirus survival tends to be higher at lower temperatures and lower relative humidity (RH),^{50, 63, 238, 284} though infectious virus can persist on surfaces for several days in typical office or hospital conditions.²⁸⁴ • SARS can persist with trace infectivity for up to 28 days at refrigerated temperatures (4°C) on surfaces.⁵⁰ • One hour after aerosolization approximately 63% of airborne MERS virus remained viable in a simulated office environment (25°C, 75% RH).²³⁵ • Porous hospital materials, including paper and cotton cloth, maintain infectious SARS-CoV for a shorter time than non-porous material.¹⁵⁶
<p>What do we need to know?</p>	<p>Additional testing on SARS-CoV-2, as opposed to surrogate viruses, is needed to support initial estimates of stability.</p> <ul style="list-style-type: none"> • Stability of SARS-CoV-2 in aerosol, droplets, and other matrices (mucus/sputum, feces) • Particle size distribution (e.g., droplet, large droplet, and true aerosol distribution) • Duration of SARS-CoV-2 infectivity via fomites and surfaces (contact hazard) • Stability of SARS-CoV-2 on PPE (e.g., Tyvek, nitrile, etc.) • Evidence for seasonality in transmission, or other environmental impacts (UV, temperature, humidity)

SARS-CoV-2 (COVID-19)	Decontamination – What are effective methods to kill the agent in the environment?
<p>What do we know?</p>	<p>Soap and water, as well as common alcohol and chlorine-based cleaners, hand sanitizers, and disinfectants are effective at inactivating SARS-CoV-2 on hands and surfaces.</p> <p><i>SARS-CoV-2</i></p> <ul style="list-style-type: none"> Alcohol-based hand rubs are effective at inactivating SARS-CoV-2.¹⁵³ Chlorine bleach (1%, 2%), 70% ethanol and 0.05% chlorhexidine are effective against live virus in lab tests.⁷³ Twice-daily cleaning with sodium dichloroisocyanurate decontaminated surfaces in COVID-19 patient hospital rooms.²²¹ EPA has released a list of SARS-CoV-2 disinfectants, but solutions were not tested on live virus.¹¹ <p><i>Other Coronaviruses</i></p> <ul style="list-style-type: none"> Chlorine-based³⁰³ and ethanol-based⁸¹ solutions are recommended. Heat treatment (56°C) is sufficient to kill coronaviruses,^{238, 333} though effectiveness depends partly on protein in the sample.²³⁸ 70% ethanol, 50% isopropanol, sodium hypochlorite (0.02% bleach), and UV radiation can inactivate several coronaviruses (MHV and CCV).²⁵⁸ Ethanol-based biocides effectively disinfect coronaviruses dried on surfaces, including ethanol containing gels similar to hand sanitizer.^{135, 309} Surface spray disinfectants such as Mikrobac, Dismozon, and Korsolex are effective at reducing infectivity of the closely related SARS-CoV after 30 minutes of contact.²³⁷ Coronaviruses may be resistant to heat inactivation for up to 7 days when stabilized in stool.²⁷⁸⁻²⁷⁹ Coronaviruses are more stable in matrixes such as respiratory sputum.⁹⁷ <p>Methods for decontaminating N95 masks have been approved by the FDA under an Emergency Use Authorization (EUA).</p> <ul style="list-style-type: none"> Researchers have identified four methods capable of decontaminating N95 respirators while maintaining physical integrity (fit factor): UV radiation, heating to 70°C, and vaporized hydrogen peroxide (VHP).¹⁰⁸ Ethanol (70%) was associated with loss of physical integrity.¹⁰⁸ Hydrogen peroxide vapor (VHP) can repeatedly decontaminate N95 respirators.²⁴⁸ Devices capable of decontaminating 80,000 masks per day have been granted Emergency Use Authorization from the FDA.¹⁰¹ The FDA has issued an Emergency Use Authorization for a system capable of decontaminating 10 N95 masks at a time using devices already present in many US hospitals.⁴¹
<p>What do we need to know?</p>	<p>Additional decontamination studies, particularly with regard to PPE and other items in short supply, are needed.</p> <ul style="list-style-type: none"> What is the minimal contact time for disinfectants? Does contamination with human fluids/waste alter disinfectant efficacy profiles? How effective is air filtration at reducing transmission in healthcare, airplanes, and public spaces? Are landfills and wastewater treatment plants effective at inactivating SARS-CoV-2? Is heat or UV decontamination effective to clean N95 masks, respirators and other types of PPE for multi-use?

SARS-CoV-2 (COVID-19)	PPE – What PPE is effective, and who should be using it?
<p>What do we know?</p>	<p>The effectiveness of PPE for SARS-CoV-2 is currently unknown, and data from other related coronaviruses are used for guidance. Healthcare workers are at high risk of acquiring COVID-19, even with recommended PPE.</p> <ul style="list-style-type: none"> • Healthcare worker illnesses²⁷⁶ demonstrates human-to-human transmission despite isolation, PPE, and infection control.²⁶⁰ • Risk of transmission to healthcare workers appears high, with up to 20% of healthcare workers in Lombardy, Italy becoming infected.²⁴³ • Over 50% of US healthcare workers infected with COVID-19 report work in a healthcare setting as their single source of exposure.⁴⁵ • “Healthcare personnel entering the room [of SARS-CoV-2 patients] should use standard precautions, contact precautions, airborne precautions, and use eye protection (e.g., goggles or a face shield).”⁵⁶ • WHO indicates healthcare workers should wear clean long-sleeve gowns as well as gloves.³⁰² • Using a fluorescent simulant, researchers found contamination on exposed skin on healthcare workers while performing intubations.¹⁰⁶ Clothing and PPE that covers all skin may reduce exposure to pathogens.^{106, 296} • Respirators (NIOSH-certified N95, EUFFP2 or equivalent) are recommended for those dealing with possible aerosols.³⁰³ Additional protection, such as a Powered Air Purifying Respirator (PAPR) with a full hood, should be considered for high-risk procedures (i.e., intubation, ventilation).⁴³ • Particular attention should be paid to the potential for transmission via exhaled air during supportive respiratory procedures.¹¹⁹ • There is evidence both for¹⁸⁴ and against²²¹ the detection of SARS-CoV-2 RNA via air sampling in patient rooms and other hospital areas. • Research at Johns Hopkins Center for Health Security has provided initial estimates of PPE needs in the US: 7.8 billion gloves, 668 million gowns, 360 million surgical masks, and 136 million N95 or similar respirators.²⁸¹ • KN95 respirators are, under certain conditions, approved for use under FDA Emergency Use Authorization.¹⁰² <p>Masks may be effective at slowing transmission.</p> <ul style="list-style-type: none"> • Surgical face masks, respirators and homemade face masks may prevent transmission of coronaviruses from infectious individuals (with or without symptoms) to other individuals.^{88, 168, 282} Surgical masks were associated with a significant reduction in the amount of seasonal coronavirus (not SARS-CoV-2) expressed as aerosol particles (<5 μm) compared to not wearing a mask.¹⁶⁸ Other preliminary work has failed to document protective efficacy of surgical or cotton masks,²³ and more SARS-CoV-2 specific research is needed. • On 4/3/2020, the US CDC recommended wearing cloth face masks in public where social distancing measures are difficult to maintain.⁵⁷ • The efficacy of homemade PPE, made with T-shirts, bandanas, or similar materials, is less than standard PPE, but may offer some protection if no other options are available.^{75, 87, 245}
<p>What do we need to know?</p>	<p>Most PPE recommendations have not been made on SARS-CoV-2 data, and comparative efficacy of different PPE for different tasks (e.g., intubation) is unknown. Identification of efficacious PPE for healthcare workers is critical due to their high rates of infection.</p> <ul style="list-style-type: none"> • What is the importance of aerosol transmission (particles <5μm)? What is the effective distance of spread via droplet or aerosol? • How effective are barriers such as N95 respirators or surgical masks for SARS-CoV-2? • What is the appropriate PPE for first responders? Airport screeners? • What are proper procedures for reducing spread and transmission rates in medical facilities? • How effective are homemade masks at reducing SARS-CoV-2 transmission?

SARS-CoV-2 (COVID-19)	Forensics – Natural vs intentional use? Tests to be used for attribution.
<p>What do we know?</p>	<p>All current evidence supports the natural emergence of SARS-CoV-2 via a bat and possible intermediate mammal species.</p> <ul style="list-style-type: none"> • Genomic analysis places SARS-CoV-2 into the beta-coronavirus clade, with close relationship to bat coronaviruses. The SARS-CoV-2 virus is distinct from SARS-CoV-1 and MERS viruses.⁹³ • Genomic analysis suggests that SARS-CoV-2 is a natural variant, and is unlikely to be human-derived or otherwise created by “recombination” with other circulating strains of coronavirus.^{15, 336} • Genomic data support at least two plausible origins of SARS-CoV-2: “(i) natural selection in a non-human animal host prior to zoonotic transfer, and (ii) natural selection in humans following zoonotic transfer.”¹⁵ Both scenarios are consistent with the observed genetic changes found in all known SARS-CoV-2 isolates. • Some SARS-CoV-2 genomic evidence indicates a close relationship with pangolin coronaviruses,³¹⁰ and data suggest that pangolins may be a natural host for beta-coronaviruses.¹⁷⁹⁻¹⁸⁰ Additional research is needed. • A novel bat coronavirus (RmYN02) has been identified in China with an insertion in the viral furin cleavage site. While distinct from the insertion in SARS-CoV-2, this evidence shows that such insertions can occur naturally.³³⁵ • Additionally, “[...] SARS-CoV-2 is not derived from any previously used virus backbone,” reducing the likelihood of laboratory origination,¹⁵ and “[...] genomic evidence does not support the idea that SARS-CoV-2 is a laboratory construct, [though] it is currently impossible to prove or disprove the other theories of its origin.”¹⁵ • Work with other coronaviruses has indicated that heparan sulfate dependence can be an indicator of prior cell passage, due to a mutation in the previous furin enzyme recognition motif.⁹⁰
<p>What do we need to know?</p>	<p>Identifying the intermediate species between bats and humans would aid in reducing potential spillover from a natural source. Wide sampling of bats, other wild animals, and humans is needed to address the origin of SARS-CoV-2.</p> <ul style="list-style-type: none"> • What tests for attribution exist for coronavirus emergence? • What is the identity of the intermediate species? • Are there closely related circulating coronaviruses in bats or other animals with the novel PRRA cleavage site found in SARS-CoV-2?

SARS-CoV-2 (COVID-19)	Genomics – How does the disease agent compare to previous strains?
<p>What do we know?</p>	<p>Current evidence suggests that SARS-CoV-2 accumulates substitutions and mutations at a similar rate as other coronaviruses. Mutations and deletions in specific portions of the SARS-CoV-2 genome have not been linked to any changes in transmission or disease severity, though modeling work is attempting to identify possible changes.</p> <ul style="list-style-type: none"> • There have been no documented cases of SARS-CoV-2 prior to December 2019. Preliminary genomic analyses, however, suggest that the first human cases of SARS-CoV-2 emerged between 10/19/2019 and 12/17/2019.^{16, 29, 240} • The mutation rate of SARS-CoV-2 is estimated to be similar to other RNA viruses (e.g., SARS, Ebola, Zika), and is currently calculated to be 1.04×10^{-3} substitutions per site per year (n=116 genomes).¹²⁵ • Pangolin coronaviruses are closely related to both SARS-CoV-2 and closely related bat coronaviruses. Phylogenetic analysis suggests that SARS-CoV-2 is of bat origin, but is closely related to pangolin coronavirus.¹⁷⁹⁻¹⁸⁰ • The SARS-CoV-2 Spike protein, which mediates entry into host cells and is the major determinant of host range, is very similar to the SARS-CoV-1 Spike protein.¹⁸⁹ The rest of the genome is more closely related to two separate bat¹⁸⁹ and pangolin¹⁸⁰ coronaviruses. • An analysis of SARS-CoV-2 sequences from Singapore has identified a large nucleotide (382 bp) deletion in ORF-8.²⁷² In Arizona, researchers identified an 81-base pair deletion (removing 27 amino acids) in the ORF-7a protein, indicating that mutations can be detected by routine sentinel surveillance. The function of these deletions are unknown at this time.¹²⁸ • A recent report of virus mutations within patients needs more research.¹⁴⁷ Additional analysis of data suggests the results may be due to experimental methods.^{116, 320} • Structural modeling suggests that observed changes in the genetic sequence of the SARS-CoV-2 Spike protein may enhance binding of the virus to human ACE2 receptors.²²² More specifically, changes to two residues (Q493 and N501) are linked with improving the stability of the virus-receptor binding complex.²²² Additionally, structural modeling identified several existing mutations that may enhance the stability of the receptor binding domain, potentially increasing binding efficacy.²²³ Infectivity assays are needed to validate the genotypic changes and possible phenotypic results identified in these studies. • A key difference between SARS-CoV-2 and other beta-coronaviruses is the presence of a polybasic furin cleavage site in the Spike protein (insertion of a PRRA amino acid sequence between S1 and S2).⁸³ • The US CDC is launching a national genomics consortium to assess SARS-CoV-2 genomic changes over time.⁵² • Preliminary phylogenetic analysis indicates at least three major SARS-CoV-2 clades that represent broad regions, though this is likely to change as additional genomes are sampled.¹¹⁰ To date there are no known differences in disease severity due to infection with different strains of SARS-CoV-2.
<p>What do we need to know?</p>	<p>Research linking genetic changes to differences in phenotype (e.g., transmissibility, virulence, progression in patients) is needed.</p> <ul style="list-style-type: none"> • Are there similar genomic differences in the progression of coronavirus strains from bat to intermediate species to human? • Are there different strains or clades of circulating virus? If so, do they differ in virulence?

Table 1. Definitions of commonly-used acronyms

Acronym/Term	Definition	Description
ACE2	Angiotensin-converting enzyme 2	Acts as a receptor for SARS-CoV, allowing entry into human cells
Airborne transmission	Aerosolization of infectious particles	Aerosolized particles can spread for long distances (e.g., between hospital rooms via HVAC systems). Particles generally <5 μm.
ARDS	Acute respiratory distress syndrome	Leakage of fluid into the lungs which inhibits respiration and leads to death
Attack rate	Proportion of “at-risk” individuals who develop infection	Defined in terms of “at-risk” population such as schools or households, defines the proportion of individuals in those populations who become infected after contact with an infectious individual
CCV	Canine coronavirus	Canine coronavirus
CFR	Case Fatality Rate	Number of deaths divided by confirmed patients
CoV	Coronavirus	Virus typified by crown-like structures when viewed under electron microscope
COVID-19	Coronavirus disease 19	Official name for the disease caused by the SARS-CoV-2 virus.
Droplet transmission	Sneezing, coughing	Transmission via droplets requires relatively close contact (e.g., within 6 feet)
ELISA	Enzyme-linked immunosorbent assay	Method for serological testing of antibodies
Fomite	Inanimate vector of disease	Surfaces such as hospital beds, doorknobs, healthcare worker gowns, faucets, etc.
HCW	Healthcare worker	Doctors, nurses, technicians dealing with patients or samples
Incubation period	Time between infection and symptom onset	Time between infection and onset of symptoms typically establishes guidelines for isolating patients before transmission is possible
Infectious period	Length of time an individual can transmit infection to others	Reducing the infectious period is a key method of reducing overall transmission; hospitalization, isolation, and quarantine are all effective methods
Intranasal	Agent deposited into external nares of subject	Simulates inhalation exposure by depositing liquid solution of pathogen/virus into the nose of a test animal, where it is then taken up by the respiratory system.
MERS	Middle-East Respiratory Syndrome	Coronavirus with over 2,000 cases in regional outbreak since 2012
MHV	Mouse hepatitis virus	Coronavirus surrogate
Nosocomial	Healthcare- or hospital-associated infections	Characteristic of SARS and MERS outbreaks, lead to refinement of infection control procedures
PCR	Polymerase chain reaction	PCR (or real-time [RT] or quantitative [Q] PCR) is a method of increasing the amount of genetic material in a sample, which is then used for diagnostic testing to confirm the presence of SARS-CoV-2
PFU	Plaque forming unit	Measurement of the number of infectious virus particles as determined by plaque forming assay. A measurement of sample infectivity.
PPE	Personal protective equipment	Gowns, masks, gloves, and any other measures used to prevent spread between individuals
R ₀	Basic reproduction number	A measure of transmissibility. Specifically, the average number of new infections caused by a typical infectious individual in a wholly susceptible population.

Acronym/Term	Definition	Description
SARS	Severe Acute Respiratory Syndrome	Coronavirus with over 8,000 cases in global 2002-2003 outbreak
SARS-CoV-2	Severe acute respiratory syndrome coronavirus 2	Official name for the virus previously known as 2019-nCoV.
Serial interval	Length of time between symptom onset of successive cases in a transmission chain	The serial interval can be used to estimate R_0 , and is useful for estimating the rate of outbreak spread
Superspreading	One individual responsible for an abnormally large number of secondary infections	Superspreading can be caused by high variance in the distribution of secondary cases caused by a single individual; most individuals infect very few people, while some infect a large number, even with the same average number of secondary infections
TCID ₅₀	50% Tissue Culture Infectious Dose	The number of infectious units which will infect 50% of tissue culture monolayers. A measurement of sample infectivity.
Transgenic	Genetically modified	In this case, animal models modified to be more susceptible to MERS and/or SARS by adding proteins or receptors necessary for infection



Literature Cited:

1. (U) China approves first anti-viral drug against coronavirus Covid-19. *Pharmaceutical Technology* 2020.
2. (U) Coronavirus diagnosed at mink farms in North Brabant. *NOS* 2020.
3. (U) Coronavirus Survey Reveals 13.9% In New York Have COVID-19 Antibodies, Cuomo Says. *CBS* 2020.
4. (U) A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults 2020.
<https://clinicaltrials.gov/ct2/show/NCT04280705>
5. (U) Phase I, Open-Label, Dose-Ranging Study of the Safety and Immunogenicity of 2019-nCoV Vaccine (mRNA-1273) in Healthy Adults 2020.
<https://clinicaltrials.gov/ct2/show/record/NCT04283461?term=mrna-1273&draw=2&rank=1>
6. (U) Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) — United States, February 12–March 16, 2020. . *MMWR* 2020.
https://www.cdc.gov/mmwr/volumes/69/wr/mm6912e2.htm?s_cid=mm6912e2_w#suggestedcitation
7. (U) Tocilizumab improves significantly clinical outcomes of patients with moderate or severe COVID-19 pneumonia. Assistance Publique - Hôpitaux de Paris/Universities/INSERM-REACTing COVID-19 academic research collaboration: 2020. <https://www.aphp.fr/contenu/tocilizumab-improves-significantly-clinical-outcomes-patients-moderate-or-severe-covid-19>
8. (U) [Wuhan Pneumonia] The Hospital Authority stated that 2 critically ill patients needed external life support treatment. <https://www.singtao.ca/4037242/2020-01-14/news-%E3%80%90%E6%AD%A6%E6%BC%A2%E8%82%BA%E7%82%8E%E3%80%91%E9%86%AB%E7%AE%A1%E5%B1%80%E6%8C%872%E5%90%8D%E9%87%8D%E7%97%87%E7%97%85%E6%82%A3%E9%9C%80%E9%AB%94%E5%A4%96%E7%94%9F%E5%91%BD%E6%94%AF%E6%8C%81%E6%B2%BB%E7%99%82/?variant=zh-hk>.
9. (U) AAAS, You may be able to spread coronavirus just by breathing, new report finds. *Science* 2 April, 2020.
10. (U) Adams, E. R.; Anand, R.; Andersson, M. I.; Auckland, K.; Baillie, J. K.; Barnes, E.; Bell, J.; Berry, T.; Bibi, S.; Carroll, M.; Chinnakannan, S.; Clutterbuck, E.; Cornall, R. J.; Crook, D. W.; De Silva, T.; Dejnirattisai, W.; Dingle, K. E.; Dold, C.; Eyre, D. W.; Farmer, H.; Hoosdally, S. J.; Hunter, A.; Jeffrey, K.; Klenerman, P.; Knight, J.; Knowles, C.; Kwok, A. J.; Leuschner, U.; Liu, C.; Lopez-Camacho, C.; Matthews, P. C.; McGivern, H.; Mentzer, A. J.; Milton, J.; Mongkolsapaya, J.; Moore, S. C.; Oliveira, M. S.; Pereira, F.; Peto, T.; Ploeg, R. J.; Pollard, A.; Prince, T.; Roberts, D. J.; Rudkin, J. K.; Sreaton, G. R.; Semple, M. G.; Skelly, D. T.; Smith, E. N.; Staves, J.; Stuart, D.; Supasa, P.; Surik, T.; Tsang, P.; Turtle, L.; Walker, A. S.; Wang, B.; Washington, C.; Watkins, N.; Whitehouse, J.; Beer, S.; Levin, R.; Espinosa, A.; Georgiou, D.; Martinez Garrido, J. C.; Thraves, H.; Perez Lopez, E.; del Rocio Fernandez Mendoza, M.; Sobrino Diaz, A. J.; Sanchez, V., Evaluation of antibody testing for SARS-Cov-2 using ELISA and lateral flow immunoassays. *medRxiv* 2020, 2020.04.15.20066407.
<https://www.medrxiv.org/content/medrxiv/early/2020/04/20/2020.04.15.20066407.full.pdf>
11. (U) Agency, U. S. E. P., EPA’s Registered Antimicrobial Products for Use Against Novel Coronavirus SARS-CoV-2, the Cause of COVID-19. <https://www.epa.gov/pesticide-registration/list-n-disinfectants-use-against-sars-cov-2>.
12. (U) Agrawal, A. S.; Garron, T.; Tao, X.; Peng, B. H.; Wakamiya, M.; Chan, T. S.; Couch, R. B.; Tseng, C. T., Generation of a transgenic mouse model of Middle East respiratory syndrome coronavirus infection and disease. *J Virol* 2015, 89 (7), 3659-70.
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4403411/pdf/zjv3659.pdf>
13. (U) Altmann, D. M.; Douek, D. C.; Boyton, R. J., What policy makers need to know about COVID-19 protective immunity. *The Lancet* 2020. [https://doi.org/10.1016/S0140-6736\(20\)30985-5](https://doi.org/10.1016/S0140-6736(20)30985-5)

14. (U) Amanat, F.; Krammer, F., SARS-CoV-2 vaccines: status report. *Journal of Immunology* **2020**, Early View. <https://marlin-prod.literatumonline.com/pb-assets/journals/research/immunity/SARS-CoV-2%20vaccines%20status%20report.pdf>
15. (U) Andersen, K. G.; Rambaut, A.; Lipkin, W. I.; Holmes, E. C.; Garry, R. F., The proximal origin of SARS-CoV-2. *Nature Medicine* **2020**. <https://doi.org/10.1038/s41591-020-0820-9>
16. (U) Anderson, K., Estimates of the clock and TMRCA for 2019-nCoV based on 27 genomes. <http://virological.org/t/clock-and-tmrca-based-on-27-genomes/347> (accessed 01/26/2020).
17. (U) Arentz, M.; Yim, E.; Klaff, L.; Lokhandwala, S.; Riedo, F. X.; Chong, M.; Lee, M., Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State. *JAMA* **2020**. <https://doi.org/10.1001/jama.2020.4326>
18. (U) Argenziano, M. G.; Bruce, S. L.; Slater, C. L.; Tiao, J. R.; Baldwin, M. R.; Barr, R. G.; Chang, B. P.; Chau, K. H.; Choi, J. J.; Gavin, N.; Goyal, P.; Mills, A. M.; Patel, A. A.; Romney, M.-L. S.; Safford, M. M.; Schluger, N. W.; Sengupta, S.; Sobieszczyk, M. E.; Zucker, J. E.; Asadourian, P. A.; Bell, F. M.; Boyd, R.; Cohen, M. F.; Colquhoun, M. I.; Colville, L. A.; de Jonge, J. H.; Dershowitz, L. B.; Dey, S. A.; Eiseman, K. A.; Girvin, Z. P.; Goni, D. T.; Harb, A. A.; Herzik, N.; Householder, S.; Karaaslan, L. E.; Lee, H.; Lieberman, E.; Ling, A.; Lu, R.; Shou, A. Y.; Sisti, A. C.; Snow, Z. E.; Sperring, C. P.; Xiong, Y.; Zhou, H. W.; Natarajan, K.; Hripcsak, G.; Chen, R., Characterization and Clinical Course of 1000 Patients with COVID-19 in New York: retrospective case series. *medRxiv* **2020**, 2020.04.20.20072116. <https://www.medrxiv.org/content/medrxiv/early/2020/04/22/2020.04.20.20072116.full.pdf>
19. (U) Arons, M. M.; Hatfield, K. M.; Reddy, S. C.; Kimball, A.; James, A.; Jacobs, J. R.; Taylor, J.; Spicer, K.; Bardossy, A. C.; Oakley, L. P.; Tanwar, S.; Dyal, J. W.; Harney, J.; Chisty, Z.; Bell, J. M.; Methner, M.; Paul, P.; Carlson, C. M.; McLaughlin, H. P.; Thornburg, N.; Tong, S.; Tamin, A.; Tao, Y.; Uehara, A.; Harcourt, J.; Clark, S.; Brostrom-Smith, C.; Page, L. C.; Kay, M.; Lewis, J.; Montgomery, P.; Stone, N. D.; Clark, T. A.; Honein, M. A.; Duchin, J. S.; Jernigan, J. A., Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility. *New England Journal of Medicine* **2020**. <https://www.nejm.org/doi/full/10.1056/NEJMoa2008457>
20. (U) Assunção, M., Iceland's coronavirus testing suggests 50% of cases have no symptoms. *NY Daily News* 01 April, 2020.
21. (U) Auld, S.; Caridi-Scheible, M.; Blum, J. M.; Robichaux, C. J.; Kraft, C. S.; Jacob, J. T.; Jabaley, C. S.; Carpenter, D.; Kaplow, R.; Hernandez, A. C.; Adelman, M. W.; Martin, G. S.; Coopersmith, C. M.; Murphy, D. J., ICU and ventilator mortality among critically ill adults with COVID-19. *medRxiv* **2020**, 2020.04.23.20076737. <https://www.medrxiv.org/content/medrxiv/early/2020/04/26/2020.04.23.20076737.full.pdf>
22. (U) Aziz, M.; Fatima, R.; Assaly, R., Elevated Interleukin-6 and Severe COVID-19: A Meta-Analysis. *J Med Virol* **2020**.
23. (U) Bae, S.; Kim, M.-C.; Kim, J. Y.; Cha, H.-H.; Lim, J. S.; Jung, J.; Kim, M.-J.; Oh, D. K.; Lee, M.-K.; Choi, S.-H.; Sung, M.; Hong, S.-B.; Chung, J.-W.; Kim, S.-H., Effectiveness of Surgical and Cotton Masks in Blocking SARS-CoV-2: A Controlled Comparison in 4 Patients. *Annals of Internal Medicine* **2020**. <https://doi.org/10.7326/M20-1342>
24. (U) Bai, H. X.; Wang, R.; Xiong, Z.; Hsieh, B.; Chang, K.; Halsey, K.; Tran, T. M. L.; Choi, J. W.; Wang, D. C.; Shi, L. B.; Mei, J.; Jiang, X. L.; Pan, I.; Zeng, Q. H.; Hu, P. F.; Li, Y. H.; Fu, F. X.; Huang, R. Y.; Sebro, R.; Yu, Q. Z.; Atalay, M. K.; Liao, W. H., AI Augmentation of Radiologist Performance in Distinguishing COVID-19 from Pneumonia of Other Etiology on Chest CT. *Radiology* **2020**, 201491.
25. (U) Bai, Y.; Yao, L.; Wei, T.; Tian, F.; Jin, D.-Y.; Chen, L.; Wang, M., Presumed Asymptomatic Carrier Transmission of COVID-19. *JAMA*.
26. (U) Bao, L.; Deng, W.; Gao, H.; Xiao, C.; Liu, J.; Xue, J.; Lv, Q.; Liu, J.; Yu, P.; Xu, Y.; Qi, F.; Qu, Y.; Li, F.; Xiang, Z.; Yu, H.; Gong, S.; Liu, M.; Wang, G.; Wang, S.; Song, Z.; Zhao, W.; Han, Y.; Zhao, L.; Liu, X.; Wei, Q.; Qin, C., Reinfection could not occur in SARS-CoV-2 infected rhesus macaques. *bioRxiv* **2020**,

2020.03.13.990226.

<https://www.biorxiv.org/content/biorxiv/early/2020/03/14/2020.03.13.990226.full.pdf>

27. (U) Barnard, D. L.; Hubbard, V. D.; Burton, J.; Smee, D. F.; Morrey, J. D.; Otto, M. J.; Sidwell, R. W., Inhibition of severe acute respiratory syndrome-associated coronavirus (SARSCoV) by calpain inhibitors and beta-D-N4-hydroxycytidine. *Antivir Chem Chemother* **2004**, *15* (1), 15-22.

<https://journals.sagepub.com/doi/pdf/10.1177/095632020401500102>

28. (U) BBC, Coronavirus: California declares emergency after death. *BBC* 2020.

29. (U) Bedford, T.; Neher, R., Genomic epidemiology of novel coronavirus (nCoV) using data from GISAID. <https://nextstrain.org/ncov>.

30. (U) Belhadi, D.; Peiffer-Smadja, N.; Yazdanpanah, Y.; Mentré, F.; Laouénan, C., A brief review of antiviral drugs evaluated in registered clinical trials for COVID-19. *medRxiv* **2020**, 2020.03.18.20038190.

<https://www.medrxiv.org/content/medrxiv/early/2020/03/20/2020.03.18.20038190.full.pdf>

31. (U) Bendavid, E.; Mulaney, B.; Sood, N.; Shah, S.; Ling, E.; Bromley-Dulfano, R.; Lai, C.; Weissberg, Z.; Saavedra, R.; Tedrow, J.; Tversky, D.; Bogan, A.; Kupiec, T.; Eichner, D.; Gupta, R.; Ioannidis, J.; Bhattacharya, J., COVID-19 Antibody Seroprevalence in Santa Clara County, California. *medRxiv* **2020**, 2020.04.14.20062463.

<https://www.medrxiv.org/content/medrxiv/early/2020/04/17/2020.04.14.20062463.full.pdf>

32. (U) Bessière, F.; Rocca, H.; Delinière, A.; Charrière, R.; Chevalier, P.; Argaud, L.; Cour, M., Assessment of QT Intervals in a Case Series of Patients With Coronavirus Disease 2019 (COVID-19) Infection Treated With Hydroxychloroquine Alone or in Combination With Azithromycin in an Intensive Care Unit. *JAMA Cardiology* **2020**. <https://doi.org/10.1001/jamacardio.2020.1787>

33. (U) BGI, BGI Responds to Novel Coronavirus with Real-Time Detection Kits, Deploys Emergency Team to Wuhan. 2020. <https://www.bgi.com/global/company/news/bgi-responds-to-novel-coronavirus-with-real-time-detection-kits-deploys-emergency-team-to-wuhan/>

34. (U) Bi, Q.; Wu, Y.; Mei, S.; Ye, C.; Zou, X.; Zhang, Z.; Liu, X.; Wei, L.; Truelove, S. A.; Zhang, T.; Gao, W.; Cheng, C.; Tang, X.; Wu, X.; Wu, Y.; Sun, B.; Huang, S.; Sun, Y.; Zhang, J.; Ma, T.; Lessler, J.; Feng, T., Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study. *Lancet Infect Dis* **2020**.

[https://www.thelancet.com/journals/laninf/article/PIIS1473-3099\(20\)30287-5/fulltext](https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30287-5/fulltext)

35. (U) Biotech, M., Mesa Biotech Receives Emergency Use Authorization from FDA for a 30 Minute Point of Care Molecular COVID-19 Test. Mesa Biotech: 2020.

<https://www.mesabiotech.com/news/euacoronavirus>

36. (U) Bonow, R. O.; Hernandez, A. F.; Turakhia, M., Hydroxychloroquine, Coronavirus Disease 2019, and QT Prolongation. *JAMA Cardiology* **2020**. <https://doi.org/10.1001/jamacardio.2020.1782>

37. (U) Borba, M. G. S.; Val, F. F. A.; Sampaio, V. S.; Alexandre, M. A. A.; Melo, G. C.; Brito, M.; Mourão, M. P. G.; Brito-Sousa, J. D.; Baía-da-Silva, D.; Guerra, M. V. F.; Hajjar, L. A.; Pinto, R. C.; Balieiro, A. A. S.; Pacheco, A. G. F.; Santos, J. D. O., Jr; Naveca, F. G.; Xavier, M. S.; Siqueira, A. M.; Schwarzbald, A.; Croda, J.; Nogueira, M. L.; Romero, G. A. S.; Bassat, Q.; Fontes, C. J.; Albuquerque, B. C.; Daniel-Ribeiro, C.-T.; Monteiro, W. M.; Lacerda, M. V. G.; Team, f. t. C.-. Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. *JAMA Network Open* **2020**, *3* (4), e208857-e208857. <https://doi.org/10.1001/jamanetworkopen.2020.8857>

38. (U) Borrell, B., New York clinical trial quietly tests heartburn remedy against coronavirus. *Science* 2020.

39. (U) Bouaziz, J.; Duong, T.; Jachiet, M.; Velter, C.; Lestang, P.; Cassius, C.; Arsouze, A.; Domergue Than Trong, E.; Bagot, M.; Begon, E.; Sulimovic, L.; Rybojad, M., Vascular skin symptoms in COVID-19: a french observational study. *Journal of the European Academy of Dermatology and Venereology n/a* (n/a).

<https://onlinelibrary.wiley.com/doi/abs/10.1111/jdv.16544>

40. (U) Branswell, H., Sanofi announces it will work with HHS to develop a coronavirus vaccine. Statnews, Ed. 2020. <https://www.statnews.com/2020/02/18/sanofi-announces-it-will-work-with-hhs-to-develop-coronavirus-vaccine/>
41. (U) Brennan, Z., FDA issues 2nd EUA for decontamination system for N95 masks. *Regulatory Focus* 2020.
42. (U) Brosseau, L. M., COMMENTARY: COVID-19 transmission messages should hinge on science. <http://www.cidrap.umn.edu/news-perspective/2020/03/commentary-covid-19-transmission-messages-should-hinge-science>.
43. (U) Brosseau, L. M.; Jones, R., Commentary: Protecting health workers from airborne MERS-CoV - learning from SARS. <http://www.cidrap.umn.edu/news-perspective/2014/05/commentary-protecting-health-workers-airborne-mers-cov-learning-sars>.
44. (U) Bryner, J., First US infant death linked to COVID-19 reported in Illinois. *LiveScience* 2020.
45. (U) Burrer, S. L.; de Perio, M. A.; Hughes, M. M.; Kuhar, D. T.; Luckhaupt, S. E.; McDaniel, C. J.; Porter, R. M.; Silk, B.; Stuckey, M. J.; Walters, M., Characteristics of health care personnel with COVID-19—United States, February 12–April 9, 2020. **2020**.
46. (U) Callow, K.; Parry, H.; Sergeant, M.; Tyrrell, D., The time course of the immune response to experimental coronavirus infection of man. *Epidemiology & Infection* **1990**, *105* (2), 435-446.
47. (U) Cao, B.; Wang, Y.; Wen, D.; Liu, W.; Wang, J.; Fan, G.; Ruan, L.; Song, B.; Cai, Y.; Wei, M.; Li, X.; Xia, J.; Chen, N.; Xiang, J.; Yu, T.; Bai, T.; Xie, X.; Zhang, L.; Li, C.; Yuan, Y.; Chen, H.; Li, H.; Huang, H.; Tu, S.; Gong, F.; Liu, Y.; Wei, Y.; Dong, C.; Zhou, F.; Gu, X.; Xu, J.; Liu, Z.; Zhang, Y.; Li, H.; Shang, L.; Wang, K.; Li, K.; Zhou, X.; Dong, X.; Qu, Z.; Lu, S.; Hu, X.; Ruan, S.; Luo, S.; Wu, J.; Peng, L.; Cheng, F.; Pan, L.; Zou, J.; Jia, C.; Wang, J.; Liu, X.; Wang, S.; Wu, X.; Ge, Q.; He, J.; Zhan, H.; Qiu, F.; Guo, L.; Huang, C.; Jaki, T.; Hayden, F. G.; Horby, P. W.; Zhang, D.; Wang, C., A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19. *New England Journal of Medicine* **2020**.
<https://www.nejm.org/doi/full/10.1056/NEJMoa2001282>
48. (U) Cao, W.; Liu, X.; Bai, T.; Fan, H.; Hong, K.; Song, H.; Han, Y.; Lin, L.; Ruan, L.; Li, T., High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with Coronavirus Disease 2019. *Open Forum Infectious Diseases* **2020**. <https://doi.org/10.1093/ofid/ofaa102>
49. (U) Casadevall, A.; Pirofski, L.-a., The convalescent sera option for containing COVID-19. *The Journal of Clinical Investigation* **2020**, *130* (4). <https://doi.org/10.1172/JCI138003>
50. (U) Casanova, L. M.; Jeon, S.; Rutala, W. A.; Weber, D. J.; Sobsey, M. D., Effects of air temperature and relative humidity on coronavirus survival on surfaces. *Applied and environmental microbiology* **2010**, *76* (9), 2712-2717. <https://www.ncbi.nlm.nih.gov/pubmed/20228108>
51. (U) CDC, 2019 Novel Coronavirus RT-PCR Identification Protocols. <https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-detection-instructions.html>.
52. (U) CDC, CDC launches national viral genomics consortium to better map SARS-CoV-2 transmission. Centers for Disease Control and Prevention: 2020. <https://www.cdc.gov/media/releases/2020/p0501-SARS-CoV-2-transmission-map.html>
53. (U) CDC, Confirmation of COVID-19 in Two Pet Cats in New York. Centers for Disease Control and Prevention: 2020. <https://www.cdc.gov/media/releases/2020/s0422-covid-19-cats-NYC.html>
54. (U) CDC, Confirmed 2019-nCoV Cases Globally. <https://www.cdc.gov/coronavirus/2019-ncov/locations-confirmed-cases.html>.
55. (U) CDC, Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease 2019 (COVID-19). <https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html>.
56. (U) CDC, Interim healthcare infection prevention and control recommendations for patients under investigation for 2019 novel coronavirus. <https://www.cdc.gov/coronavirus/2019-ncov/infection-control.html>.

57. (U) CDC, Recommendation Regarding the Use of Cloth Face Coverings, Especially in Areas of Significant Community-Based Transmission. **2020**. <https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/cloth-face-cover.html>
58. (U) CDC, Situation summary. <https://www.cdc.gov/coronavirus/2019-nCoV/summary.html>.
59. (U) CDC, Symptoms of Coronavirus. <https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html>.
60. (U) CDC, C., China's CDC detects a large number of new coronaviruses in the South China seafood market in Wuhan http://www.chinacdc.cn/yw_9324/202001/t20200127_211469.html (accessed 01/27/2020).
61. (U) Chan, J. F.-W.; Yuan, S.; Kok, K.-H.; To, K. K.-W.; Chu, H.; Yang, J.; Xing, F.; Liu, J.; Yip, C. C.-Y.; Poon, R. W.-S.; Tsoi, H.-W.; Lo, S. K.-F.; Chan, K.-H.; Poon, V. K.-M.; Chan, W.-M.; Ip, J. D.; Cai, J.-P.; Cheng, V. C.-C.; Chen, H.; Hui, C. K.-M.; Yuen, K.-Y., A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. *The Lancet* **2020**. <https://www.sciencedirect.com/science/article/pii/S0140673620301549>
62. (U) Chan, J. F.; Zhang, A. J.; Yuan, S.; Poon, V. K.; Chan, C. C.; Lee, A. C.; Chan, W. M.; Fan, Z.; Tsoi, H. W.; Wen, L.; Liang, R.; Cao, J.; Chen, Y.; Tang, K.; Luo, C.; Cai, J. P.; Kok, K. H.; Chu, H.; Chan, K. H.; Sridhar, S.; Chen, Z.; Chen, H.; To, K. K.; Yuen, K. Y., Simulation of the clinical and pathological manifestations of Coronavirus Disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility. *Clin Infect Dis* **2020**. <https://www.ncbi.nlm.nih.gov/pubmed/32215622>
63. (U) Chan, K. H.; Peiris, J. S.; Lam, S. Y.; Poon, L. L.; Yuen, K. Y.; Seto, W. H., The Effects of Temperature and Relative Humidity on the Viability of the SARS Coronavirus. *Adv Virol* **2011**, *2011*, 734690. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3265313/pdf/AV2011-734690.pdf>
64. (U) Changzheng, L. J. L., Experts in the medical treatment team: Wuhan's unexplained viral pneumonia patients can be controlled more. <https://www.cn-healthcare.com/article/20200110/content-528579.html>.
65. (U) Chen, C.; Cao, M.; Peng, L.; Guo, X.; Yang, F.; Wu, W.; Chen, L.; Yang, Y.; Liu, Y.; Wang, F., Coronavirus Disease-19 Among Children Outside Wuhan, China. *SSRN* **2020**. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3546071
66. (U) Chen, C.; Huang, J.; Cheng, Z.; Wu, J.; Chen, S.; Zhang, Y.; Chen, B.; Lu, M.; Luo, Y.; Zhang, J.; Yin, P.; Wang, X., Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial. *medRxiv* **2020**, 2020.03.17.20037432. <https://www.medrxiv.org/content/medrxiv/early/2020/03/20/2020.03.17.20037432.full.pdf>
67. (U) Chen, H.; Guo, J.; Wang, C.; Luo, F.; Yu, X.; Zhang, W.; Li, J.; Zhao, D.; Xu, D.; Gong, Q., Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. *The Lancet* **2020**, *395* (10226), 809-815.
68. (U) Chen, L.; Li, Q.; Zheng, D.; Jiang, H.; Wei, Y.; Zou, L.; Feng, L.; Xiong, G.; Sun, G.; Wang, H.; Zhao, Y.; Qiao, J., Clinical Characteristics of Pregnant Women with Covid-19 in Wuhan, China. *New England Journal of Medicine* **2020**. <https://www.nejm.org/doi/full/10.1056/NEJMc2009226>
69. (U) Chen, N.; Zhou, M.; Dong, X.; Qu, J.; Gong, F.; Han, Y.; Qiu, Y.; Wang, J.; Liu, Y.; Wei, Y.; Xia, J.; Yu, T.; Zhang, X.; Zhang, L., Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet* **2020**. <https://www.ncbi.nlm.nih.gov/pubmed/32007143>
70. (U) Chen, Y.; Peng, H.; Wang, L.; Zhao, Y.; Zeng, L.; Gao, H.; Liu, Y., Infants Born to Mothers With a New Coronavirus (COVID-19). *Frontiers in Pediatrics* **2020**, *8* (104). <https://www.frontiersin.org/article/10.3389/fped.2020.00104>
71. (U) Cheng, H.-Y.; Jian, S.-W.; Liu, D.-P.; Ng, T.-C.; Huang, W.-T.; Lin, H.-H.; Team, f. t. T. C.-O. I., Contact Tracing Assessment of COVID-19 Transmission Dynamics in Taiwan and Risk at Different

Exposure Periods Before and After Symptom Onset. *JAMA Internal Medicine* **2020**.

<https://doi.org/10.1001/jamainternmed.2020.2020>

72. (U) Cheruiyot, I.; Henry, B. M.; Lippi, G., Is there evidence of intra-uterine vertical transmission potential of COVID-19 infection in samples tested by quantitative RT-PCR? *Eur J Obstet Gynecol Reprod Biol* **2020**.

73. (U) Chin, A.; Chu, J.; Perera, M.; Hui, K.; Yen, H.-L.; Chan, M.; Peiris, M.; Poon, L., Stability of SARS-CoV-2 in different environmental conditions. *medRxiv* **2020**, 2020.03.15.20036673.

<https://www.medrxiv.org/content/medrxiv/early/2020/03/27/2020.03.15.20036673.full.pdf>

74. (U) Chin, A. W. H.; Chu, J. T. S.; Perera, M. R. A.; Hui, K. P. Y.; Yen, H.-L.; Chan, M. C. W.; Peiris, M.; Poon, L. L. M., Stability of SARS-CoV-2 in different environmental conditions. *The Lancet Microbe*.

[https://doi.org/10.1016/S2666-5247\(20\)30003-3](https://doi.org/10.1016/S2666-5247(20)30003-3)

75. (U) Chughtai, A. A.; Seale, H.; MacIntyre, C. R., Use of cloth masks in the practice of infection control—evidence and policy gaps. *Int J Infect Control* **2013**, *9* (3), doi: 10.3396/IJIC.v9i3.020.13.

76. (U) Coalition, C.-C. R., Global coalition to accelerate COVID-19 clinical research in resource-limited settings. *The Lancet* **2020**. <http://www.sciencedirect.com/science/article/pii/S0140673620307984>

77. (U) Cockrell, A. S.; Yount, B. L.; Scobey, T.; Jensen, K.; Douglas, M.; Beall, A.; Tang, X.-C.; Marasco, W. A.; Heise, M. T.; Baric, R. S., A mouse model for MERS coronavirus-induced acute respiratory distress syndrome. *Nature microbiology* **2016**, *2* (2), 1-11.

78. (U) Cohen, J., COVID-19 vaccine protects monkeys from new coronavirus, Chinese biotech reports. *Science* **2020**.

79. (U) Cohen, J., Mining coronavirus genomes for clues to the outbreak's origins. *Science* **2020**.

80. (U) Cohen, J., Wuhan seafood market may not be source of novel virus spreading globally.

<https://www.sciencemag.org/news/2020/01/wuhan-seafood-market-may-not-be-source-novel-virus-spreading-globally> (accessed 01/27/2020).

81. (U) Control, E. E. C. f. D. P. a., *Interim guidance for environmental cleaning in non-healthcare facilities exposed to SARS-CoV-2*; European Centre for Disease Prevention and Control: European Centre for Disease Prevention and Control, 2020. <https://www.ecdc.europa.eu/en/publications-data/interim-guidance-environmental-cleaning-non-healthcare-facilities-exposed-2019#no-link>

82. (U) Corman, V. M.; Landt, O.; Kaiser, M.; Molenkamp, R.; Meijer, A.; Chu, D. K.; Bleicker, T.; Brunink, S.; Schneider, J.; Schmidt, M. L.; Mulders, D. G.; Haagmans, B. L.; van der Veer, B.; van den Brink, S.; Wijsman, L.; Goderski, G.; Romette, J. L.; Ellis, J.; Zambon, M.; Peiris, M.; Goossens, H.; Reusken, C.; Koopmans, M. P.; Drosten, C., Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Euro Surveill* **2020**, *25* (3). <https://www.ncbi.nlm.nih.gov/pubmed/31992387>

83. (U) Coutard, B.; Valle, C.; de Lamballerie, X.; Canard, B.; Seidah, N.; Decroly, E., The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. *Antiviral research* **2020**, *176*, 104742.

84. (U) Cowling, B. J.; Ali, S. T.; Ng, T. W. Y.; Tsang, T. K.; Li, J. C. M.; Fong, M. W.; Liao, Q.; Kwan, M. Y.; Lee, S. L.; Chiu, S. S.; Wu, J. T.; Wu, P.; Leung, G. M., Impact assessment of non-pharmaceutical interventions against COVID-19 and influenza in Hong Kong: an observational study. *medRxiv* **2020**, 2020.03.12.20034660.

<https://www.medrxiv.org/content/medrxiv/early/2020/03/16/2020.03.12.20034660.full.pdf>

85. (U) Daily, H., Wuhan Institute of Virology, Chinese Academy of Sciences and others have found that 3 drugs have a good inhibitory effect on new coronavirus. Chen, L., Ed. **2020**.

http://news.cnhubei.com/content/2020-01/28/content_12656365.html

86. (U) Dandekar, R.; Barbastathis, G., Neural Network aided quarantine control model estimation of global Covid-19 spread. *arXiv preprint arXiv:2004.02752* **2020**.

87. (U) Dato, V. M.; Hostler, D.; Hahn, M. E., Simple respiratory mask. *Emerg Infect Dis* **2006**, *12* (6), 1033-4. <https://www.ncbi.nlm.nih.gov/pubmed/16752475>

88. (U) Davies, A.; Thompson, K. A.; Giri, K.; Kafatos, G.; Walker, J.; Bennett, A., Testing the efficacy of homemade masks: would they protect in an influenza pandemic? *Disaster Med Public Health Prep* **2013**, 7 (4), 413-8. <https://www.ncbi.nlm.nih.gov/pubmed/24229526>
89. (U) De Albuquerque, N.; Baig, E.; Ma, X.; Zhang, J.; He, W.; Rowe, A.; Habal, M.; Liu, M.; Shalev, I.; Downey, G. P.; Gorczynski, R.; Butany, J.; Leibowitz, J.; Weiss, S. R.; McGilvray, I. D.; Phillips, M. J.; Fish, E. N.; Levy, G. A., Murine hepatitis virus strain 1 produces a clinically relevant model of severe acute respiratory syndrome in A/J mice. *J Virol* **2006**, 80 (21), 10382-94. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1641767/pdf/0747-06.pdf>
90. (U) de Haan, C. A. M.; Haijema, B. J.; Schellen, P.; Schreur, P. W.; te Lintelo, E.; Vennema, H.; Rottier, P. J. M., Cleavage of Group 1 Coronavirus Spike Proteins: How Furin Cleavage Is Traded Off against Heparan Sulfate Binding upon Cell Culture Adaptation. *Journal of Virology* **2008**, 82 (12), 6078-6083. <https://jvi.asm.org/content/jvi/82/12/6078.full.pdf>
91. (U) Dediego, M. L.; Pewe, L.; Alvarez, E.; Rejas, M. T.; Perlman, S.; Enjuanes, L., Pathogenicity of severe acute respiratory coronavirus deletion mutants in hACE-2 transgenic mice. *Virology* **2008**, 376 (2), 379-389. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2810402/>
92. (U) Deng, W.; Bao, L.; Gao, H.; Xiang, Z.; Qu, Y.; Song, Z.; Gong, S.; Liu, J.; Liu, J.; Yu, P.; Qi, F.; Xu, Y.; Li, F.; Xiao, C.; Lv, Q.; Xue, J.; Wei, Q.; Liu, M.; Wang, G.; Wang, S.; Yu, H.; Liu, X.; Zhao, W.; Han, Y.; Qin, C., Ocular conjunctival inoculation of SARS-CoV-2 can cause mild COVID-19 in Rhesus macaques. *bioRxiv* **2020**.
93. (U) Dong, N.; Yang, X.; Ye, L.; Chen, K.; Chan, E. W.-C.; Yang, M.; Chen, S., Genomic and protein structure modelling analysis depicts the origin and infectivity of 2019-nCoV, a new coronavirus which caused a pneumonia outbreak in Wuhan, China. *bioRxiv* **2020**, 2020.01.20.913368. <https://www.biorxiv.org/content/biorxiv/early/2020/01/22/2020.01.20.913368.full.pdf>
94. (U) Dong, Y.; Mo, X.; Hu, Y.; Qi, X.; Jiang, F.; Jiang, Z.; Tong, S., Epidemiological Characteristics of 2143 Pediatric Patients With 2019 Coronavirus Disease in China. *Pediatrics* **2020**, e20200702. <https://pediatrics.aappublications.org/content/pediatrics/early/2020/03/16/peds.2020-0702.full.pdf>
95. (U) Du, Z.; Xu, X.; Wu, Y.; Wang, L.; Cowling, B. J.; Meyers, L. A., COVID-19 serial interval estimates based on confirmed cases in public reports from 86 Chinese cities. *medRxiv* **2020**, 2020.04.23.20075796. <https://www.medrxiv.org/content/medrxiv/early/2020/04/27/2020.04.23.20075796.full.pdf>
96. (U) Du, Z.; Xu, X.; Wu, Y.; Wang, L.; Cowling, B. J.; Meyers, L. A., The serial interval of COVID-19 from publicly reported confirmed cases. *medRxiv* **2020**, 2020.02.19.20025452. <https://www.medrxiv.org/content/medrxiv/early/2020/03/13/2020.02.19.20025452.full.pdf>
97. (U) Duan, S.; Zhao, X.; Wen, R.; Huang, J.-j.; Pi, G.; Zhang, S.; Han, J.; Bi, S.; Ruan, L.; Dong, X.-p., Stability of SARS coronavirus in human specimens and environment and its sensitivity to heating and UV irradiation. *Biomedical and environmental sciences: BES* **2003**, 16 (3), 246-255.
98. (U) Duan, S. M.; Zhao, X. S.; Wen, R. F.; Huang, J. J.; Pi, G. H.; Zhang, S. X.; Han, J.; Bi, S. L.; Ruan, L.; Dong, X. P., Stability of SARS coronavirus in human specimens and environment and its sensitivity to heating and UV irradiation. *Biomed Environ Sci* **2003**, 16 (3), 246-55.
99. (U) Endeman, H.; van der Zee, P.; van Genderen, M. E.; van den Akker, J. P. C.; Gommers, D., Progressive respiratory failure in COVID-19: a hypothesis. *The Lancet Infectious Diseases* **2020**. [https://doi.org/10.1016/S1473-3099\(20\)30366-2](https://doi.org/10.1016/S1473-3099(20)30366-2)
100. (U) EuroTimes, Pfizer/BioNTech target April vaccine trial launch. *EuroTimes* 2020.
101. (U) FDA, *Emergency Use Authorization*; Food and Drug Administration: 2020. <https://www.fda.gov/media/136529/download>
102. (U) FDA, FAQs on Shortages of Surgical Masks and Gowns. <https://www.fda.gov/medical-devices/personal-protective-equipment-infection-control/faqs-shortages-surgical-masks-and-gowns#kn95>.

103. (U) FDA, *ID NOW COVID-19*; Food and Drug Administration: 2020.
<https://www.fda.gov/media/136525/download>
104. (U) FDA, *Investigational COVID-19 Convalescent Plasma - Emergency INDs*; Food and Drug Administration: 2020. <https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/investigational-covid-19-convalescent-plasma-emergency-ind>
105. (U) FDA, Policy for Diagnostics Testing in Laboratories Certified to Perform High Complexity Testing under CLIA prior to Emergency Use Authorization for Coronavirus Disease-2019 during the Public Health Emergency; Immediately in Effect Guidance for Industry and Food and Drug Administration Staff. 2020. <https://www.regulations.gov/docket?D=FDA-2020-D-0987>
106. (U) Feldman, O.; Meir, M.; Shavit, D.; Idelman, R.; Shavit, I., Exposure to a Surrogate Measure of Contamination From Simulated Patients by Emergency Department Personnel Wearing Personal Protective Equipment. *JAMA* **2020**. <https://doi.org/10.1001/jama.2020.6633>
107. (U) Ferguson, N.; Laydon, D.; Nedjati-Gilani, G.; Imai, N.; Ainslie, K.; Baguelin, M.; Bhatia, S.; Boonyasiri, A.; Cucunuba, Z.; Cuomo-Dannenburg, G.; Dighe, A.; Dorigatti, I.; Fu, H.; Gaythorpe, K.; Green, W.; Hamlet, A.; Hinsley, W.; Okell, L.; van Elsland, S.; Thompson, H.; Verity, R.; Volz, E.; Wang, H.; Wang, Y.; Walker, P.; Walters, C.; Winskill, P.; Whittaker, C.; Donnelly, C.; Riley, S.; Ghani, A., *Impact of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demand*; 2020. <https://www.imperial.ac.uk/media/imperial-college/medicine/sph/ide/gida-fellowships/Imperial-College-COVID19-NPI-modelling-16-03-2020.pdf>
108. (U) Fischer, R.; Morris, D. H.; van Doremalen, N.; Sarchette, S.; Matson, J.; Bushmaker, T.; Yinda, C. K.; Seifert, S.; Gamble, A.; Williamson, B.; Judson, S.; de Wit, E.; Lloyd-Smith, J.; Munster, V., Assessment of N95 respirator decontamination and re-use for SARS-CoV-2. *medRxiv* **2020**, 2020.04.11.20062018. <https://www.medrxiv.org/content/medrxiv/early/2020/04/24/2020.04.11.20062018.full.pdf>
109. (U) Fitzpatrick, J.; DeSalvo, K., Helping public health officials combat COVID-19. Google: 2020. <https://www.blog.google/technology/health/covid-19-community-mobility-reports?hl=en>
110. (U) Forster, P.; Forster, L.; Renfrew, C.; Forster, M., Phylogenetic network analysis of SARS-CoV-2 genomes. *Proceedings of the National Academy of Sciences* **2020**, *117* (17), 9241-9243. <https://www.pnas.org/content/pnas/117/17/9241.full.pdf>
111. (U) Frank, H. K.; Enard, D.; Boyd, S. D., Exceptional diversity and selection pressure on SARS-CoV and SARS-CoV-2 host receptor in bats compared to other mammals. *bioRxiv* **2020**, 2020.04.20.051656. <https://www.biorxiv.org/content/biorxiv/early/2020/04/20/2020.04.20.051656.full.pdf>
112. (U) Gao, Q.; Bao, L.; Mao, H.; Wang, L.; Xu, K.; Yang, M.; Li, Y.; Zhu, L.; Wang, N.; Lv, Z.; Gao, H.; Ge, X.; Kan, B.; Hu, Y.; Liu, J.; Cai, F.; Jiang, D.; Yin, Y.; Qin, C.; Li, J.; Gong, X.; Lou, X.; Shi, W.; Wu, D.; Zhang, H.; Zhu, L.; Deng, W.; Li, Y.; Lu, J.; Li, C.; Wang, X.; Yin, W.; Zhang, Y.; Qin, C., Rapid development of an inactivated vaccine for SARS-CoV-2. *bioRxiv* **2020**, 2020.04.17.046375. <https://www.biorxiv.org/content/biorxiv/early/2020/04/19/2020.04.17.046375.full.pdf>
113. (U) Garg, S., Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019—COVID-NET, 14 States, March 1–30, 2020. *MMWR. Morbidity and Mortality Weekly Report* **2020**, *69*.
114. (U) Gatto, M.; Bertuzzo, E.; Mari, L.; Miccoli, S.; Carraro, L.; Casagrandi, R.; Rinaldo, A., Spread and dynamics of the COVID-19 epidemic in Italy: Effects of emergency containment measures. *Proceedings of the National Academy of Sciences* **2020**, 202004978. <https://www.pnas.org/content/pnas/early/2020/04/22/2004978117.full.pdf>
115. (U) Gautret, P.; Lagier, J.-C.; Parola, P.; Meddeb, L.; Mailhe, M.; Doudier, B.; Courjon, J.; Giordanengo, V.; Vieira, V. E.; Dupont, H. T., Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. *International Journal of Antimicrobial Agents* **2020**, 105949.

116. (U) GitHub Inc., Reproducible analyses for rejecting rare genomic inversions in SARS-CoV-2. https://github.com/alexcrischristoph/sars_cov_2_inversion (accessed 04 April).
117. (U) Gold, J. A., Characteristics and Clinical Outcomes of Adult Patients Hospitalized with COVID-19—Georgia, March 2020. *MMWR. Morbidity and Mortality Weekly Report* **2020**, 69.
118. (U) Goyal, P.; Choi, J. J.; Pinheiro, L. C.; Schenck, E. J.; Chen, R.; Jabri, A.; Satlin, M. J.; Campion, T. R.; Nahid, M.; Ringel, J. B.; Hoffman, K. L.; Alshak, M. N.; Li, H. A.; Wehmeyer, G. T.; Rajan, M.; Reshetnyak, E.; Hupert, N.; Horn, E. M.; Martinez, F. J.; Gulick, R. M.; Safford, M. M., Clinical Characteristics of Covid-19 in New York City. *New England Journal of Medicine* **2020**.
<https://www.nejm.org/doi/full/10.1056/NEJMc2010419>
119. (U) Guan, L.; Zhou, L.; Zhang, J.; Peng, W.; Chen, R., More awareness is needed for severe acute respiratory syndrome coronavirus 2019 transmission through exhaled air during non-invasive respiratory support: experience from China. *European Respiratory Journal* **2020**, 55 (3), 2000352.
<https://erj.ersjournals.com/content/erj/55/3/2000352.full.pdf>
120. (U) Guan, W.-j.; Ni, Z.-y.; Hu, Y.; Liang, W.-h.; Ou, C.-q.; He, J.-x.; Liu, L.; Shan, H.; Lei, C.-l.; Hui, D. S. C.; Du, B.; Li, L.-j.; Zeng, G.; Yuen, K.-Y.; Chen, R.-c.; Tang, C.-l.; Wang, T.; Chen, P.-y.; Xiang, J.; Li, S.-y.; Wang, J.-l.; Liang, Z.-j.; Peng, Y.-x.; Wei, L.; Liu, Y.; Hu, Y.-h.; Peng, P.; Wang, J.-m.; Liu, J.-y.; Chen, Z.; Li, G.; Zheng, Z.-j.; Qiu, S.-q.; Luo, J.; Ye, C.-j.; Zhu, S.-y.; Zhong, N.-s., Clinical Characteristics of Coronavirus Disease 2019 in China. *New England Journal of Medicine* **2020**, 382, 1708-1720.
https://www.nejm.org/doi/full/10.1056/NEJMoa2002032?query=recirc_artType_railA_article
121. (U) Guo, Z.; Wang, Z.; Zhang, S.; Li, X.; Li, L.; Li, C.; Cui, Y.; Fu, R.; Dong, Y.; Chi, X., Aerosol and Surface Distribution of Severe Acute Respiratory Syndrome Coronavirus 2 in Hospital Wards, Wuhan, China, 2020. *Emerging infectious diseases* **2020**, 26 (7).
122. (U) He, R.; Lu, Z.; Zhang, L.; Fan, T.; Xiong, R.; Shen, X.; Feng, H.; Meng, H.; Lin, W.; Jiang, W.; Geng, Q., The clinical course and its correlated immune status in COVID-19 pneumonia. *Journal of Clinical Virology* **2020**, 127, 104361. <http://www.sciencedirect.com/science/article/pii/S1386653220301037>
123. (U) He, X.; Lau, E. H. Y.; Wu, P.; Deng, X.; Wang, J.; Hao, X.; Lau, Y. C.; Wong, J. Y.; Guan, Y.; Tan, X.; Mo, X.; Chen, Y.; Liao, B.; Chen, W.; Hu, F.; Zhang, Q.; Zhong, M.; Wu, Y.; Zhao, L.; Zhang, F.; Cowling, B. J.; Li, F.; Leung, G. M., Temporal dynamics in viral shedding and transmissibility of COVID-19. *Nature Medicine* **2020**. <https://doi.org/10.1038/s41591-020-0869-5>
124. (U) HHS, 2019-nCoV Update. 2020. https://www.hhs.gov/live/live-2/index.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fmedia%2Fpress%2Freleases%2F2020%2Fa0128-hhs-coronavirus-update.html#11465
125. (U) Hill, V.; Rambaut, A., Phylodynamic analysis of SARS-CoV-2 | Update 2020-03-06. *Virological*: 2020. <http://virological.org/t/phylodynamic-analysis-of-sars-cov-2-update-2020-03-06/420>
126. (U) Hinton, D., qSARS-CoV-2 IgG/IgM Rapid Test- Letter of Authorization. FDA, Ed. FDA: 2020.
<https://www.fda.gov/media/136622/download>
127. (U) Hoehl, S.; Berger, A.; Kortenbusch, M.; Cinatl, J.; Bojkova, D.; Rabenau, H.; Behrens, P.; Böddinghaus, B.; Götsch, U.; Naujoks, F.; Neumann, P.; Schork, J.; Tiarks-Jungk, P.; Walczok, A.; Eickmann, M.; Vehreschild, M. J. G. T.; Kann, G.; Wolf, T.; Gottschalk, R.; Ciesek, S., Evidence of SARS-CoV-2 Infection in Returning Travelers from Wuhan, China. *New England Journal of Medicine* **2020**.
<https://www.nejm.org/doi/full/10.1056/NEJMc2001899>
128. (U) Holland, L. A.; Kaelin, E. A.; Maqsood, R.; Estifanos, B.; Wu, L. I.; Varsani, A.; Halden, R. U.; Hogue, B. G.; Scotch, M.; Lim, E. S., An 81 base-pair deletion in SARS-CoV-2 ORF7a identified from sentinel surveillance in Arizona (Jan-Mar 2020). *medRxiv* **2020**, 2020.04.17.20069641.
<https://www.medrxiv.org/content/medrxiv/early/2020/04/22/2020.04.17.20069641.full.pdf>
129. (U) Houston, U. o. T. H. S. C. a., Clinical Trial Tests Stem Cell Therapy Against COVID-19. 2020.
<https://www.technologynetworks.com/biopharma/news/clinical-trial-tests-stem-cell-therapy-against-covid-19-333946>

130. (U) Hu, Q.; Cui, X.; Liu, X.; Peng, B.; Jiang, J.; Wang, X.; Li, Y.; Hu, W.; Ao, Z.; Duan, J.; Wang, X.; Zhu, L.; Guo, S.; Wu, G., The production of antibodies for SARS-CoV-2 and its clinical implication. *medRxiv* **2020**, 2020.04.20.20065953.
<https://www.medrxiv.org/content/medrxiv/early/2020/04/24/2020.04.20.20065953.full.pdf>
131. (U) Hu, Z.; Song, C.; Xu, C.; Jin, G.; Chen, Y.; Xu, X.; Ma, H.; Chen, W.; Lin, Y.; Zheng, Y.; Wang, J.; Hu, Z.; Yi, Y.; Shen, H., Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. *Science China Life Sciences* **2020**. <https://doi.org/10.1007/s11427-020-1661-4>
132. (U) Huang, C.; Wang, Y.; Li, X.; Ren, L.; Zhao, J.; Hu, Y.; Zhang, L.; Fan, G.; Xu, J.; Gu, X.; Cheng, Z.; Yu, T.; Xia, J.; Wei, Y.; Wu, W.; Xie, X.; Yin, W.; Li, H.; Liu, M.; Xiao, Y.; Gao, H.; Guo, L.; Xie, J.; Wang, G.; Jiang, R.; Gao, Z.; Jin, Q.; Wang, J.; Cao, B., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *The Lancet* **2020**. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(20\)30183-5/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30183-5/fulltext)
133. (U) Huang, R.; Xia, J.; Chen, Y.; Shan, C.; Wu, C., A family cluster of SARS-CoV-2 infection involving 11 patients in Nanjing, China. *The Lancet Infectious Diseases* **2020**, *20* (5), 534-535.
[https://doi.org/10.1016/S1473-3099\(20\)30147-X](https://doi.org/10.1016/S1473-3099(20)30147-X)
134. (U) Huang, Y.; Lyu, X.; Li, D.; Wang, Y.; Wang, L.; Zou, W.; Wei, Y.; Wu, X., A cohort study of 223 patients explores the clinical risk factors for the severity diagnosis of COVID-19. *medRxiv* **2020**, 2020.04.18.20070656.
<https://www.medrxiv.org/content/medrxiv/early/2020/04/24/2020.04.18.20070656.full.pdf>
135. (U) Hulkower, R. L.; Casanova, L. M.; Rutala, W. A.; Weber, D. J.; Sobsey, M. D., Inactivation of surrogate coronaviruses on hard surfaces by health care germicides. *American journal of infection control* **2011**, *39* (5), 401-407. <https://www.sciencedirect.com/science/article/pii/S0196655310009004>
136. (U) Hulme, O. J.; Wagenmakers, E.-J.; Damkier, P.; Madelung, C. F.; Siebner, H. R.; Helweg-Larsen, J.; Gronau, Q.; Benfield, T. L.; Madsen, K. H., A Bayesian reanalysis of the effects of hydroxychloroquine and azithromycin on viral carriage in patients with COVID-19. *medRxiv* **2020**, 2020.03.31.20048777.
<https://www.medrxiv.org/content/medrxiv/early/2020/04/28/2020.03.31.20048777.full.pdf>
137. (U) ICNARC, *ICNARC report on COVID-19 in critical care, 24 April 2020*; Intensive Care National Audit and Research Centre: 2020. <https://www.icnarc.org/DataServices/Attachments/Download/c5a62b13-6486-ea11-9125-00505601089b>
138. (U) IDEXX, Leading Veterinary Diagnostic Company Sees No COVID-19 Cases in Pets. IDEXX: 2020.
<https://www.idexx.com/en/about-idexx/news/no-covid-19-cases-pets/>
139. (U) ISAC, Statement on IJAA paper. International Society of Antimicrobial Chemotherapy: 2020.
<https://www.isac.world/news-and-publications/official-isac-statement>
140. (U) Iwata, K.; Doi, A.; Miyakoshi, C., Was School Closure Effective in Mitigating Coronavirus Disease 2019 (COVID-19)? Time Series Analysis Using Bayesian Inference. **2020**.
141. (U) JHU, Coronavirus COVID-19 Global Cases by Johns Hopkins CSSE.
<https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6>.
142. (U) Jin, J.-M.; Bai, P.; He, W.; Wu, F.; Liu, X.-F.; Han, D.-M.; Liu, S.; Yang, J.-K., Gender Differences in Patients With COVID-19: Focus on Severity and Mortality. *Frontiers in Public Health* **2020**, *8* (152).
<https://www.frontiersin.org/article/10.3389/fpubh.2020.00152>
143. (U) Jing, C.; Wenjie, S.; Jianping, H.; Michelle, G.; Jing, W.; Guiqing, H., Indirect Virus Transmission in Cluster of COVID-19 Cases, Wenzhou, China, 2020. *Emerging Infectious Disease journal* **2020**, *26* (6).
https://wwwnc.cdc.gov/eid/article/26/6/20-0412_article
144. (U) Johndrow, J. E.; Lum, K.; Ball, P., Estimating SARS-CoV-2-positive Americans using deaths-only data. *arXiv preprint arXiv:2004.02605* **2020**.

145. (U) Johnson, J. a., Johnson & Johnson Announces a Lead Vaccine Candidate for COVID-19; Landmark New Partnership with U.S. Department of Health & Human Services; and Commitment to Supply One Billion Vaccines Worldwide for Emergency Pandemic Use. Johnson and Johnson: 2020.
<https://www.jnj.com/johnson-johnson-announces-a-lead-vaccine-candidate-for-covid-19-landmark-new-partnership-with-u-s-department-of-health-human-services-and-commitment-to-supply-one-billion-vaccines-worldwide-for-emergency-pandemic-use>
146. (U) Joseph, A., CDC developing serologic tests that could reveal full scope of U.S. coronavirus outbreak. *STAT* 2020.
147. (U) Karamitros, T.; Papadopoulou, G.; Bousali, M.; Mexias, A.; Tsiodras, S.; Mentis, A., SARS-CoV-2 exhibits intra-host genomic plasticity and low-frequency polymorphic quasispecies. *bioRxiv* **2020**, 2020.03.27.009480. <http://biorxiv.org/content/early/2020/03/28/2020.03.27.009480.abstract>
148. (U) Kim, Y.-I.; Kim, S.-G.; Kim, S.-M.; Kim, E.-H.; Park, S.-J.; Yu, K.-M.; Chang, J.-H.; Kim, E. J.; Lee, S.; Casel, M. A. B.; Um, J.; Song, M.-S.; Jeong, H. W.; Lai, V. D.; Kim, Y.; Chin, B. S.; Park, J.-S.; Chung, K.-H.; Foo, S.-S.; Poo, H.; Mo, I.-P.; Lee, O.-J.; Webby, R. J.; Jung, J. U.; Choi, Y. K., Infection and Rapid Transmission of SARS-CoV-2 in Ferrets. *Cell Host & Microbe* **2020**.
<http://www.sciencedirect.com/science/article/pii/S1931312820301876>
149. (U) Kissler, S. M.; Tedijanto, C.; Goldstein, E.; Grad, Y. H.; Lipsitch, M., Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period. *Science* **2020**, eabb5793.
<https://science.sciencemag.org/content/sci/early/2020/04/14/science.abb5793.full.pdf>
150. (U) Klok, F.; Kruip, M.; van der Meer, N.; Arbous, M.; Gommers, D.; Kant, K.; Kaptein, F.; van Paassen, J.; Stals, M.; Huisman, M., Incidence of thrombotic complications in critically ill ICU patients with COVID-19. *Thrombosis Research* **2020**.
151. (U) Kraemer, M. U. G.; Yang, C.-H.; Gutierrez, B.; Wu, C.-H.; Klein, B.; Pigott, D. M.; du Plessis, L.; Faria, N. R.; Li, R.; Hanage, W. P.; Brownstein, J. S.; Layan, M.; Vespignani, A.; Tian, H.; Dye, C.; Pybus, O. G.; Scarpino, S. V., The effect of human mobility and control measures on the COVID-19 epidemic in China. *Science* **2020**, eabb4218.
<https://science.sciencemag.org/content/sci/early/2020/03/25/science.abb4218.full.pdf>
152. (U) Krantz, S. G.; Rao, A. S. S., Level of under-reporting including under-diagnosis before the first peak of COVID-19 in various countries: Preliminary Retrospective Results Based on Wavelets and Deterministic Modeling. *Infection Control & Hospital Epidemiology* **2020**, 1-8.
153. (U) Kratzel, A.; Todt, D.; V'kovski, P.; Steiner, S.; Gultom, M. L.; Thao, T. T. N.; Ebert, N.; Holwerda, M.; Steinmann, J.; Niemeyer, D.; Dijkman, R.; Kampf, G.; Drosten, C.; Steinmann, E.; Thiel, V.; Pfaender, S., Efficient inactivation of SARS-CoV-2 by WHO-recommended hand rub formulations and alcohols. *bioRxiv* **2020**, 2020.03.10.986711.
<https://www.biorxiv.org/content/biorxiv/early/2020/03/17/2020.03.10.986711.full.pdf>
154. (U) Kucharski, A. J.; Russell, T. W.; Diamond, C.; Liu, Y.; Edmunds, J.; Funk, S.; Eggo, R. M.; Sun, F.; Jit, M.; Munday, J. D., Early dynamics of transmission and control of COVID-19: a mathematical modelling study. *The lancet infectious diseases* **2020**.
155. (U) Kupferschmidt, K.; Cohen, J., WHO launches global megatrial of the four most promising coronavirus treatments. *Science* 2020.
156. (U) Lai, M. Y.; Cheng, P. K.; Lim, W. W., Survival of severe acute respiratory syndrome coronavirus. *Clinical Infectious Diseases* **2005**, 41 (7), e67-e71.
<https://academic.oup.com/cid/article/41/7/e67/310340>
157. (U) Lai, S.; Ruktanonchai, N. W.; Zhou, L.; Prosper, O.; Luo, W.; Floyd, J. R.; Wesolowski, A.; Santillana, M.; Zhang, C.; Du, X.; Yu, H.; Tatem, A. J., Effect of non-pharmaceutical interventions to contain COVID-19 in China. *Nature* **2020**. <https://doi.org/10.1038/s41586-020-2293-x>
158. (U) Lam, S.; Bordin, N.; Waman, V.; Scholes, H.; Ashford, P.; Sen, N.; van Dorp, L.; Rauer, C.; Dawson, N.; Pang, C.; Abbasian, M.; Sillitoe, I.; Edwards, S.; Fraternali, F.; Lees, J.; Santini, J.; Orengo, C.,

- SARS-CoV-2 spike protein predicted to form stable complexes with host receptor protein orthologues from mammals, but not fish, birds or reptiles. *bioRxiv* **2020**, 2020.05.01.072371.
<https://www.biorxiv.org/content/biorxiv/early/2020/05/01/2020.05.01.072371.full.pdf>
159. (U) Lam, T. T.-Y.; Shum, M. H.-H.; Zhu, H.-C.; Tong, Y.-G.; Ni, X.-B.; Liao, Y.-S.; Wei, W.; Cheung, W. Y.-M.; Li, W.-J.; Li, L.-F.; Leung, G. M.; Holmes, E. C.; Hu, Y.-L.; Guan, Y., Identifying SARS-CoV-2 related coronaviruses in Malayan pangolins. *Nature* **2020**. <https://doi.org/10.1038/s41586-020-2169-0>
160. (U) Lamers, M. M.; Beumer, J.; van der Vaart, J.; Knoops, K.; Puschhof, J.; Breugem, T. I.; Ravelli, R. B. G.; Paul van Schayck, J.; Mykytyn, A. Z.; Duimel, H. Q.; van Donselaar, E.; Riesebosch, S.; Kuijpers, H. J. H.; Schippers, D.; van de Wetering, W. J.; de Graaf, M.; Koopmans, M.; Cuppen, E.; Peters, P. J.; Haagmans, B. L.; Clevers, H., SARS-CoV-2 productively infects human gut enterocytes. *Science* **2020**, eabc1669. <https://science.sciencemag.org/content/sci/early/2020/04/30/science.abc1669.full.pdf>
161. (U) Lan, L.; Xu, D.; Ye, G.; Xia, C.; Wang, S.; Li, Y.; Xu, H., Positive RT-PCR Test Results in Patients Recovered From COVID-19. *Jama* **2020**. <https://jamanetwork.com/journals/jama/fullarticle/2762452>
162. (U) Lasry, A.; Kidder, D.; Hast, M.; Poovey, J.; Sunshine, G.; Zviedrite, N.; Ahmed, F.; Ethier, K. A., Timing of community mitigation and changes in reported COVID-19 and community mobility—four US metropolitan areas, February 26–April 1, 2020. **2020**.
163. (U) Lassaunière, R.; Frische, A.; Harboe, Z. B.; Nielsen, A. C.; Fomsgaard, A.; Krogfelt, K. A.; Jørgensen, C. S., Evaluation of nine commercial SARS-CoV-2 immunoassays. *medRxiv* **2020**, 2020.04.09.20056325.
<https://www.medrxiv.org/content/medrxiv/early/2020/04/10/2020.04.09.20056325.full.pdf>
164. (U) Lau, S., Coronavirus: WHO official says there's no evidence of 'reinfected' patients in China
<https://www.scmp.com/news/china/society/article/3074045/coronavirus-who-official-says-theres-no-evidence-reinfected>.
165. (U) Lauer, S. A.; Grantz, K. H.; Bi, Q.; Jones, F. K.; Zheng, Q.; Meredith, H. R.; Azman, A. S.; Reich, N. G.; Lessler, J., The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. *Annals of Internal Medicine* **2020**.
<https://doi.org/10.7326/M20-0504>
166. (U) Lavezzo, E.; Franchin, E.; Ciavarella, C.; Cuomo-Dannenburg, G.; Barzon, L.; Del Vecchio, C.; Rossi, L.; Manganelli, R.; Loregian, A.; Navarin, N.; Abate, D.; Sciro, M.; Merigliano, S.; Decanale, E.; Vanuzzo, M. C.; Saluzzo, F.; Onelia, F.; Pacenti, M.; Parisi, S.; Carretta, G.; Donato, D.; Flor, L.; Cocchio, S.; Masi, G.; Sperduti, A.; Cattarino, L.; Salvador, R.; Gaythorpe, K. A. M.; Brazzale, A. R.; Toppo, S.; Trevisan, M.; Baldo, V.; Donnelly, C. A.; Ferguson, N. M.; Dorigatti, I.; Crisanti, A., Suppression of COVID-19 outbreak in the municipality of Vo, Italy. *medRxiv* **2020**, 2020.04.17.20053157.
<https://www.medrxiv.org/content/medrxiv/early/2020/04/18/2020.04.17.20053157.full.pdf>
167. (U) Leung, K.; Wu, J. T.; Liu, D.; Leung, G. M., First-wave COVID-19 transmissibility and severity in China outside Hubei after control measures, and second-wave scenario planning: a modelling impact assessment. *The Lancet*. [https://doi.org/10.1016/S0140-6736\(20\)30746-7](https://doi.org/10.1016/S0140-6736(20)30746-7)
168. (U) Leung, N. H. L.; Chu, D. K. W.; Shiu, E. Y. C.; Chan, K.-H.; McDevitt, J. J.; Hau, B. J. P.; Yen, H.-L.; Li, Y.; Ip, D. K. M.; Peiris, J. S. M.; Seto, W.-H.; Leung, G. M.; Milton, D. K.; Cowling, B. J., Respiratory virus shedding in exhaled breath and efficacy of face masks. *Nature Medicine* **2020**.
<https://doi.org/10.1038/s41591-020-0843-2>
169. (U) Levine, J., Scientists race to develop vaccine to deadly China coronavirus.
<https://nypost.com/2020/01/25/scientists-race-to-develop-vaccine-to-deadly-china-coronavirus/>.
170. (U) Lewis, D., Is the coronavirus airborne? Experts can't agree. *Nature* **2020**. 10.1038/d41586-020-00974-w
171. (U) Li, K.; Wohlford-Lenane, C.; Perlman, S.; Zhao, J.; Jewell, A. K.; Reznikov, L. R.; Gibson-Corley, K. N.; Meyerholz, D. K.; McCray, P. B., Jr., Middle East Respiratory Syndrome Coronavirus Causes Multiple

- Organ Damage and Lethal Disease in Mice Transgenic for Human Dipeptidyl Peptidase 4. *J Infect Dis* **2016**, 213 (5), 712-22. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747621/pdf/jiv499.pdf>
172. (U) Li, Q.; Guan, X.; Wu, P.; Wang, X.; Zhou, L.; Tong, Y.; Ren, R.; Leung, K. S. M.; Lau, E. H. Y.; Wong, J. Y.; Xing, X.; Xiang, N.; Wu, Y.; Li, C.; Chen, Q.; Li, D.; Liu, T.; Zhao, J.; Liu, M.; Tu, W.; Chen, C.; Jin, L.; Yang, R.; Wang, Q.; Zhou, S.; Wang, R.; Liu, H.; Luo, Y.; Liu, Y.; Shao, G.; Li, H.; Tao, Z.; Yang, Y.; Deng, Z.; Liu, B.; Ma, Z.; Zhang, Y.; Shi, G.; Lam, T. T. Y.; Wu, J. T.; Gao, G. F.; Cowling, B. J.; Yang, B.; Leung, G. M.; Feng, Z., Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia. *New England Journal of Medicine* **2020**. <https://www.nejm.org/doi/full/10.1056/NEJMoa2001316>
- <https://www.nejm.org/doi/10.1056/NEJMoa2001316>
173. (U) Li, R.; Pei, S.; Chen, B.; Song, Y.; Zhang, T.; Yang, W.; Shaman, J., Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV2). *Science* **2020**, eabb3221. <https://science.sciencemag.org/content/sci/early/2020/03/13/science.abb3221.full.pdf>
174. (U) Li, W.; Zhang, B.; Lu, J.; Liu, S.; Chang, Z.; Cao, P.; Liu, X.; Zhang, P.; Ling, Y.; Tao, K.; Chen, J., The characteristics of household transmission of COVID-19. *Clinical Infectious Diseases* **2020**. <https://doi.org/10.1093/cid/ciaa450>
175. (U) Li, X.; Zai, J.; Zhao, Q.; Nie, Q.; Li, Y.; Foley, B. T.; Chaillon, A., Evolutionary history, potential intermediate animal host, and cross-species analyses of SARS-CoV-2. *Journal of Medical Virology* **2020**, n/a (n/a). <https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.25731>
176. (U) Li, Y.; Qian, H.; Hang, J.; Chen, X.; Hong, L.; Liang, P.; Li, J.; Xiao, S.; Wei, J.; Liu, L.; Kang, M., Evidence for probable aerosol transmission of SARS-CoV-2 in a poorly ventilated restaurant. *medRxiv* **2020**, 2020.04.16.20067728. <https://www.medrxiv.org/content/medrxiv/early/2020/04/22/2020.04.16.20067728.full.pdf>
177. (U) Liu, A., China's CanSino Bio advances COVID-19 vaccine into phase 2 on preliminary safety data. *Fierce Pharma* **2020**.
178. (U) Liu, H.; Wang, L.-L.; Zhao, S.-J.; Kwak-Kim, J.; Mor, G.; Liao, A.-H., Why are pregnant women susceptible to viral infection: an immunological viewpoint? *Journal of Reproductive Immunology* **2020**, 103122. <http://www.sciencedirect.com/science/article/pii/S0165037820300437>
179. (U) Liu, P.; Chen, W.; Chen, J.-P., Viral Metagenomics Revealed Sendai Virus and Coronavirus Infection of Malayan Pangolins (*Manis javanica*). *Viruses* **2019**, 11 (11), 979. <https://www.mdpi.com/1999-4915/11/11/979>
180. (U) Liu, P.; Jiang, J.-Z.; Wan, X.-F.; Hua, Y.; Wang, X.; Hou, F.; Chen, J.; Zou, J.; Chen, J., Are pangolins the intermediate host of the 2019 novel coronavirus (2019-nCoV) ? *bioRxiv* **2020**, 2020.02.18.954628. <http://biorxiv.org/content/early/2020/02/20/2020.02.18.954628.abstract>
181. (U) Liu, W.; Zhang, Q.; Chen, J.; Xiang, R.; Song, H.; Shu, S.; Chen, L.; Liang, L.; Zhou, J.; You, L.; Wu, P.; Zhang, B.; Lu, Y.; Xia, L.; Huang, L.; Yang, Y.; Liu, F.; Semple, M. G.; Cowling, B. J.; Lan, K.; Sun, Z.; Yu, H.; Liu, Y., Detection of Covid-19 in Children in Early January 2020 in Wuhan, China. *New England Journal of Medicine* **2020**. <https://www.nejm.org/doi/full/10.1056/NEJMc2003717>
182. (U) Liu, Y.; Funk, S.; Flasche, S., *The Contribution of Pre-symptomatic Transmission to the COVID-19 Outbreak*; London School of Hygiene and Tropical Medicine: 2020. <https://cmmid.github.io/topics/covid19/control-measures/pre-symptomatic-transmission.html>
183. (U) Liu, Y.; Hu, G.; Wang, Y.; Zhao, X.; Ji, F.; Ren, W.; Gong, M.; Ju, X.; Li, C.; Hong, J.; Zhu, Y.; Cai, X.; Wu, J.; Lan, X.; Xie, Y.; Wang, X.; Yuan, Z.; Zhang, R.; Ding, Q., Functional and Genetic Analysis of Viral Receptor ACE2 Orthologs Reveals a Broad Potential Host Range of SARS-CoV-2. *bioRxiv* **2020**, 2020.04.22.046565. <https://www.biorxiv.org/content/biorxiv/early/2020/05/03/2020.04.22.046565.full.pdf>

184. (U) Liu, Y.; Ning, Z.; Chen, Y.; Guo, M.; Liu, Y.; Gali, N. K.; Sun, L.; Duan, Y.; Cai, J.; Westerdahl, D.; Liu, X.; Xu, K.; Ho, K.-f.; Kan, H.; Fu, Q.; Lan, K., Aerodynamic analysis of SARS-CoV-2 in two Wuhan hospitals. *Nature* **2020**. <https://doi.org/10.1038/s41586-020-2271-3>
185. (U) Liu, Y.; Yan, L.-M.; Wan, L.; Xiang, T.-X.; Le, A.; Liu, J.-M.; Peiris, M.; Poon, L. L. M.; Zhang, W., Viral dynamics in mild and severe cases of COVID-19. *The Lancet Infectious Diseases*. [https://doi.org/10.1016/S1473-3099\(20\)30232-2](https://doi.org/10.1016/S1473-3099(20)30232-2)
186. (U) Long, Q.-X.; Liu, B.-Z.; Deng, H.-J.; Wu, G.-C.; Deng, K.; Chen, Y.-K.; Liao, P.; Qiu, J.-F.; Lin, Y.; Cai, X.-F.; Wang, D.-Q.; Hu, Y.; Ren, J.-H.; Tang, N.; Xu, Y.-Y.; Yu, L.-H.; Mo, Z.; Gong, F.; Zhang, X.-L.; Tian, W.-G.; Hu, L.; Zhang, X.-X.; Xiang, J.-L.; Du, H.-X.; Liu, H.-W.; Lang, C.-H.; Luo, X.-H.; Wu, S.-B.; Cui, X.-P.; Zhou, Z.; Zhu, M.-M.; Wang, J.; Xue, C.-J.; Li, X.-F.; Wang, L.; Li, Z.-J.; Wang, K.; Niu, C.-C.; Yang, Q.-J.; Tang, X.-J.; Zhang, Y.; Liu, X.-M.; Li, J.-J.; Zhang, D.-C.; Zhang, F.; Liu, P.; Yuan, J.; Li, Q.; Hu, J.-L.; Chen, J.; Huang, A.-L., Antibody responses to SARS-CoV-2 in patients with COVID-19. *Nature Medicine* **2020**. <https://doi.org/10.1038/s41591-020-0897-1>
187. (U) Lowe, D., Hydroxychloroquine Update For April 6. (accessed April 7).
188. (U) Lu, J.; Plessis, L. d.; Liu, Z.; Hill, V.; Kang, M.; Lin, H.; Sun, J.; Francois, S.; Kraemer, M. U. G.; Faria, N. R.; McCrone, J. T.; Peng, J.; Xiong, Q.; Yuan, R.; Zeng, L.; Zhou, P.; Liang, C.; Yi, L.; Liu, J.; Xiao, J.; Hu, J.; Liu, T.; Ma, W.; Li, W.; Su, J.; Zheng, H.; Peng, B.; Fang, S.; Su, W.; Li, K.; Sun, R.; Bai, R.; Tang, X.; Liang, M.; Quick, J.; Song, T.; Rambaut, A.; Loman, N.; Raghwani, J.; Pybus, O.; Ke, C., Genomic epidemiology of SARS-CoV-2 in Guangdong Province, China. *medRxiv* **2020**, 2020.04.01.20047076. <https://www.medrxiv.org/content/medrxiv/early/2020/04/04/2020.04.01.20047076.full.pdf>
189. (U) Lu, R.; Zhao, X.; Li, J.; Niu, P.; Yang, B.; Wu, H.; Wang, W.; Song, H.; Huang, B.; Zhu, N.; Bi, Y.; Ma, X.; Zhan, F.; Wang, L.; Hu, T.; Zhou, H.; Hu, Z.; Zhou, W.; Zhao, L.; Chen, J.; Meng, Y.; Wang, J.; Lin, Y.; Yuan, J.; Xie, Z.; Ma, J.; Liu, W. J.; Wang, D.; Xu, W.; Holmes, E. C.; Gao, G. F.; Wu, G.; Chen, W.; Shi, W.; Tan, W., Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. *The Lancet* **2020**. [https://doi.org/10.1016/S0140-6736\(20\)30251-8](https://doi.org/10.1016/S0140-6736(20)30251-8)
190. (U) Lu, S.; Zhao, Y.; Yu, W.; Yang, Y.; Gao, J.; Wang, J.; Kuang, D.; Yang, M.; Yang, J.; Ma, C.; Xu, J.; Qian, X.; Li, H.; Zhao, S.; Li, J.; Wang, H.; Long, H.; Zhou, J.; Luo, F.; Ding, K.; Wu, D.; Zhang, Y.; Dong, Y.; Liu, Y.; Zheng, Y.; Lin, X.; Jiao, L.; Zheng, H.; Dai, Q.; Sun, Q.; Hu, Y.; Ke, C.; Liu, H.; Peng, X., Comparison of SARS-CoV-2 infections among 3 species of non-human primates. *bioRxiv* **2020**, 2020.04.08.031807. <https://www.biorxiv.org/content/biorxiv/early/2020/04/12/2020.04.08.031807.full.pdf>
191. (U) Lu, X.; Zhang, L.; Du, H.; Zhang, J.; Li, Y. Y.; Qu, J.; Zhang, W.; Wang, Y.; Bao, S.; Li, Y.; Wu, C.; Liu, H.; Liu, D.; Shao, J.; Peng, X.; Yang, Y.; Liu, Z.; Xiang, Y.; Zhang, F.; Silva, R. M.; Pinkerton, K. E.; Shen, K.; Xiao, H.; Xu, S.; Wong, G. W. K., SARS-CoV-2 Infection in Children. *New England Journal of Medicine* **2020**. <https://www.nejm.org/doi/full/10.1056/NEJMc2005073>
192. (U) Luo, L.; Liu, D.; Liao, X.-l.; Wu, X.-b.; Jing, Q.-l.; Zheng, J.-z.; Liu, F.-h.; Yang, S.-g.; Bi, B.; Li, Z.-h.; Liu, J.-p.; Song, W.-q.; Zhu, W.; Wang, Z.-h.; Zhang, X.-r.; Chen, P.-l.; Liu, H.-m.; Cheng, X.; Cai, M.-c.; Huang, Q.-m.; Yang, P.; Yang, X.-f.; Huang, Z.-g.; Tang, J.-l.; Ma, Y.; Mao, C., Modes of contact and risk of transmission in COVID-19 among close contacts. *medRxiv* **2020**, 2020.03.24.20042606. <https://www.medrxiv.org/content/medrxiv/early/2020/03/26/2020.03.24.20042606.full.pdf>
193. (U) Luo, W.; Majumder, M. S.; Liu, D.; Poirier, C.; Mandl, K. D.; Lipsitch, M.; Santillana, M., The role of absolute humidity on transmission rates of the COVID-19 outbreak. *medRxiv* **2020**, 2020.02.12.20022467. <https://www.medrxiv.org/content/medrxiv/early/2020/02/17/2020.02.12.20022467.full.pdf>
194. (U) Luo, Y.; Trevathan, E.; Qian, Z.; Li, Y.; Li, J.; Xiao, W.; Tu, N.; Zeng, Z.; Mo, P.; Xiong, Y.; Ye, G., Asymptomatic SARS-CoV-2 Infection in Household Contacts of a Healthcare Provider, Wuhan, China. *Emerging Infectious Disease journal* **2020**, 26 (8). https://wwwnc.cdc.gov/eid/article/26/8/20-1016_article

195. (U) Magagnoli, J.; Narendran, S.; Pereira, F.; Cummings, T.; Hardin, J. W.; Sutton, S. S.; Ambati, J., Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. *medRxiv* **2020**, 2020.04.16.20065920.
<https://www.medrxiv.org/content/medrxiv/early/2020/04/23/2020.04.16.20065920.full.pdf>
196. (U) Mahevas, M.; Tran, V.-T.; Roumier, M.; Chabrol, A.; Paule, R.; Guillaud, C.; Gallien, S.; Lepeule, R.; Szwebel, T.-A.; Lescure, X.; Schlemmer, F.; Matignon, M.; Khellaf, M.; Crickx, E.; Terrier, B.; Morbieu, C.; Legendre, P.; Dang, J.; Schoindre, Y.; Pawlotski, J.-M.; Michel, M.; Perrodeau, E.; Carlier, N.; Roche, N.; De Lastours, V.; Mouthon, L.; Audureau, E.; Ravaud, P.; Godeau, B.; Costedoat, N., No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial. *medRxiv* **2020**, 2020.04.10.20060699.
<https://www.medrxiv.org/content/medrxiv/early/2020/04/14/2020.04.10.20060699.full.pdf>
197. (U) Majumder, M.; Mandl, K., Early transmissibility assessment of a novel coronavirus in Wuhan, China. *SSRN* **2020**. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3524675
198. (U) Mallapaty, S., Coronavirus can infect cats — dogs, not so much. *Nature* **2020**.
<https://www.nature.com/articles/d41586-020-00984-8>
199. (U) Mason, M., Hundreds of thousands in L.A. County may have been infected with coronavirus, study finds. *LA Times* **2020**.
200. (U) Matthay, M. A.; Aldrich, J. M.; Gotts, J. E., Treatment for severe acute respiratory distress syndrome from COVID-19. *The Lancet Respiratory Medicine* **2020**. [https://doi.org/10.1016/S2213-2600\(20\)30127-2](https://doi.org/10.1016/S2213-2600(20)30127-2)
201. (U) McCombs, A.; Kadelka, C., A model-based evaluation of the efficacy of COVID-19 social distancing, testing and hospital triage policies. *medRxiv* **2020**, 2020.04.20.20073213.
<https://www.medrxiv.org/content/medrxiv/early/2020/04/23/2020.04.20.20073213.full.pdf>
202. (U) Medicine, U. S. N. L. o., BCG Vaccination to Protect Healthcare Workers Against COVID-19 (BRACE). <https://clinicaltrials.gov/ct2/show/NCT04327206?term=COVID-19&cond=BCG&draw=2&rank=4>.
203. (U) Medicine, U. S. N. L. o., Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19. <https://clinicaltrials.gov/ct2/show/NCT04334980>.
204. (U) Medicine, U. S. N. L. o., Immunity and Safety of Covid-19 Synthetic Minigene Vaccine. ClinicalTrials.gov: 2020. <https://clinicaltrials.gov/ct2/show/NCT04276896>
205. (U) Medicine, U. S. N. L. o., Safety and Immunity of Covid-19 aAPC Vaccine. ClinicalTrials.gov: 2020. <https://clinicaltrials.gov/ct2/show/NCT04299724>
206. (U) Mehra, M. R.; Desai, S. S.; Kuy, S.; Henry, T. D.; Patel, A. N., Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. *New England Journal of Medicine* **2020**.
<https://www.nejm.org/doi/full/10.1056/NEJMoa2007621>
207. (U) Melin, A. D.; Janiak, M. C.; Marrone, F.; Arora, P. S.; Higham, J. P., Comparative ACE2 variation and primate COVID-19 risk. *bioRxiv* **2020**, 2020.04.09.034967.
<https://www.biorxiv.org/content/biorxiv/early/2020/04/19/2020.04.09.034967.full.pdf>
208. (U) Menachery, V. D.; Dinnon, K. H.; Yount, B. L.; McAnarney, E. T.; Gralinski, L. E.; Hale, A.; Graham, R. L.; Scobey, T.; Anthony, S. J.; Wang, L.; Graham, B.; Randell, S. H.; Lipkin, W. I.; Baric, R. S., Trypsin Treatment Unlocks Barrier for Zoonotic Bat Coronavirus Infection. *Journal of Virology* **2020**, *94* (5), e01774-19. <https://jvi.asm.org/content/jvi/94/5/e01774-19.full.pdf>
209. (U) Meng, Y.; Wu, P.; Lu, W.; Liu, K.; Ma, K.; Huang, L.; Cai, J.; Zhang, H.; Qin, Y.; Sun, H.; Ding, W.; Gui, L.; Wu, P., Sex-specific clinical characteristics and prognosis of coronavirus disease-19 infection in Wuhan, China: A retrospective study of 168 severe patients. *PLoS Pathog* **2020**, *16* (4), e1008520.
210. (U) Mercurio, N. J.; Yen, C. F.; Shim, D. J.; Maher, T. R.; McCoy, C. M.; Zimetbaum, P. J.; Gold, H. S., Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without

- Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19). *JAMA Cardiology* **2020**. <https://doi.org/10.1001/jamacardio.2020.1834>
211. (U) Merow, C.; Urban, M. C., Seasonality and uncertainty in COVID-19 growth rates. *medRxiv* **2020**, 2020.04.19.20071951. <https://www.medrxiv.org/content/medrxiv/early/2020/04/22/2020.04.19.20071951.full.pdf>
212. (U) Ministry for Foreign Affairs, Large scale testing of general population in Iceland underway In *Government of Iceland*, Government of Iceland: 2020. <https://www.government.is/news/article/2020/03/15/Large-scale-testing-of-general-population-in-Iceland-underway/>
213. (U) Moriarty, L. F.; Plucinski, M. M.; Marston, B. J. e. a., Public Health Responses fo COVID-19 Outbreaks on Cruise Ships - Worldwide, February - March 2020. *MMWR* **2020**, (ePub: 23 March 2020). <https://www.cdc.gov/mmwr/volumes/69/wr/mm6912e3.htm>
214. (U) Munster, V. J.; Feldmann, F.; Williamson, B. N.; van Doremalen, N.; Pérez-Pérez, L.; Schulz, J.; Meade-White, K.; Okumura, A.; Callison, J.; Brumbaugh, B.; Avanzato, V. A.; Rosenke, R.; Hanley, P. W.; Saturday, G.; Scott, D.; Fischer, E. R.; de Wit, E., Respiratory disease and virus shedding in rhesus macaques inoculated with SARS-CoV-2. *bioRxiv* **2020**, 2020.03.21.001628. <https://www.biorxiv.org/content/biorxiv/early/2020/03/21/2020.03.21.001628.full.pdf>
215. (U) Muoio, D., Scanwell Health, myLAB Box unveil more at-home COVID-19 testing services. *MobiHealthNews* 20 March, 2020.
216. (U) Nadi, A., An at-home fingerprick blood test may help detect your exposure to coronavirus. *NBC NEWS* 04 April, 2020.
217. (U) NIH, *Fact Sheet for Patients And Parent/Caregivers - Emergency Use Authorization (EUA) Of Remdesivir For Coronavirus Disease 2019 (COVID-19)*; National Institutes of Health: 2020. <https://www.fda.gov/media/137565/download>
218. (U) NIH, NIH clinical trial of remdesivir to treat COVID-19 begins <https://www.nih.gov/news-events/news-releases/nih-clinical-trial-remdesivir-treat-covid-19-begins>.
219. (U) NIH, NIH clinical trial shows Remdesivir accelerates recovery from advanced COVID-19. National Institutes of Health: 2020. <https://www.nih.gov/news-events/news-releases/nih-clinical-trial-shows-remdesivir-accelerates-recovery-advanced-covid-19>
220. (U) Okba, N.; Müller, M.; Li, W.; Wang, C.; GeurtsvanKessel, C.; Corman, V.; Lamers, M.; Sikkema, R.; de Bruin, E.; Chandler, F., Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease 2019 Patients. *Emerging infectious diseases* **2020**, 26 (7).
221. (U) Ong, S. W. X.; Tan, Y. K.; Chia, P. Y.; Lee, T. H.; Ng, O. T.; Wong, M. S. Y.; Marimuthu, K., Air, Surface Environmental, and Personal Protective Equipment Contamination by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) From a Symptomatic Patient. *Jama* **2020**. https://jamanetwork.com/journals/jama/articlepdf/2762692/jama_ong_2020_id_200016.pdf
222. (U) Ortega, J. T.; Serrano, M. L.; Pujol, F. H.; Rangel, H. R., Role of changes in SARS-CoV-2 spike protein in the interaction with the human ACE2 receptor: An in silico analysis. *EXCLI journal* **2020**, 19, 410-417. <https://pubmed.ncbi.nlm.nih.gov/32210742>
- <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7081066/>
223. (U) Ou, J.; Zhou, Z.; Dai, R.; Zhang, J.; Lan, W.; Zhao, S.; Wu, J.; Seto, D.; Cui, L.; Zhang, G.; Zhang, Q., Emergence of RBD mutations in circulating SARS-CoV-2 strains enhancing the structural stability and human ACE2 receptor affinity of the spike protein. *bioRxiv* **2020**, 2020.03.15.991844. <https://www.biorxiv.org/content/biorxiv/early/2020/04/20/2020.03.15.991844.full.pdf>
224. (U) Pan, A.; Liu, L.; Wang, C.; Guo, H.; Hao, X.; Wang, Q.; Huang, J.; He, N.; Yu, H.; Lin, X., Association of Public Health Interventions With the Epidemiology of the COVID-19 Outbreak in Wuhan, China. *JAMA* **2020**.

225. (U) Pan, F.; Ye, T.; Sun, P.; Gui, S.; Liang, B.; Li, L.; Zheng, D.; Wang, J.; Hesketh, R. L.; Yang, L.; Zheng, C., Time Course of Lung Changes On Chest CT During Recovery From 2019 Novel Coronavirus (COVID-19) Pneumonia. *Radiology* 0 (0), 200370. <https://pubs.rsna.org/doi/abs/10.1148/radiol.2020200370>
226. (U) Paranjpe, I.; Russak, A.; De Freitas, J. K.; Lala, A.; Miotto, R.; Vaid, A.; Johnson, K. W.; Danieleto, M.; Golden, E.; Meyer, D.; Singh, M.; Somani, S.; Manna, S.; Nangia, U.; Kapoor, A.; O'Hagan, R.; O'Reilly, P. F.; Huckins, L. M.; Glowe, P.; Kia, A.; Timsina, P.; Freeman, R. M.; Levin, M. A.; Jhang, J.; Firpo, A.; Kovatch, P.; Finkelstein, J.; Aberg, J. A.; Bagiella, E.; Horowitz, C. R.; Murphy, B.; Fayad, Z. A.; Narula, J.; Nestler, E. J.; Fuster, V.; Cordon-Cardo, C.; Charney, D. S.; Reich, D. L.; Just, A. C.; Bottinger, E. P.; Charney, A. W.; Glicksberg, B. S.; Nadkarni, G., Clinical Characteristics of Hospitalized Covid-19 Patients in New York City. *medRxiv* **2020**, 2020.04.19.20062117. <https://www.medrxiv.org/content/medrxiv/early/2020/04/26/2020.04.19.20062117.full.pdf>
227. (U) Park, A., An At-Home Coronavirus Test May Be on the Way in the U.S. *TIME* 25 March, 2020.
228. (U) Park, S. W.; Champredon, D.; Earn, D. J. D.; Li, M.; Weitz, J. S.; Grenfell, B. T.; Dushoff, J., Reconciling early-outbreak preliminary estimates of the basic reproductive number and its uncertainty: a new framework and applications to the novel coronavirus (2019-nCoV) outbreak. **2020**, 1-13.
229. (U) Parri, N.; Lenge, M.; Buonsenso, D., Children with Covid-19 in Pediatric Emergency Departments in Italy. *New England Journal of Medicine* **2020**. <https://www.nejm.org/doi/full/10.1056/NEJMc2007617>
230. (U) Pastorino, B.; Touret, F.; Gilles, M.; de Lamballerie, X.; Charrel, R., Prolonged viability of SARS-CoV-2 in fomites. **2020**.
231. (U) Peuchmaurd, S., Oxford University Just Injected The First Participants in a COVID-19 Vaccine Trial. *Science Alert* **2020**.
232. (U) Pfizer, BIONTECH AND PFIZER ANNOUNCE REGULATORY APPROVAL FROM GERMAN AUTHORITY PAUL-EHRLICH-INSTITUT TO COMMENCE FIRST CLINICAL TRIAL OF COVID-19 VACCINE CANDIDATES. 2020. https://www.pfizer.com/news/press-release/press-release-detail/biontech_and_pfizer_announce_regulatory_approval_from_german_authority_paul_ehrlich_insti_tut_to_commence_first_clinical_trial_of_covid_19_vaccine_candidates
233. (U) Pigoga, J. L.; Friedman, A.; Broccoli, M.; Hirner, S.; Naidoo, A. V.; Singh, S.; Werner, K.; Wallis, L. A., Clinical and historical features associated with severe COVID-19 infection: a systematic review. *medRxiv* **2020**, 2020.04.23.20076653. <https://www.medrxiv.org/content/medrxiv/early/2020/04/27/2020.04.23.20076653.full.pdf>
234. (U) Prem, K.; Liu, Y.; Russell, T. W.; Kucharski, A. J.; Eggo, R. M.; Davies, N.; Flasche, S.; Clifford, S.; Pearson, C. A. B.; Munday, J. D.; Abbott, S.; Gibbs, H.; Rosello, A.; Quilty, B. J.; Jombart, T.; Sun, F.; Diamond, C.; Gimma, A.; van Zandvoort, K.; Funk, S.; Jarvis, C. I.; Edmunds, W. J.; Bosse, N. I.; Hellewell, J.; Jit, M.; Klepac, P., The effect of control strategies to reduce social mixing on outcomes of the COVID-19 epidemic in Wuhan, China: a modelling study. *The Lancet Public Health* **2020**. [https://doi.org/10.1016/S2468-2667\(20\)30073-6](https://doi.org/10.1016/S2468-2667(20)30073-6)
235. (U) Pyankov, O. V.; Bodnev, S. A.; Pyankova, O. G.; Agranovski, I. E., Survival of aerosolized coronavirus in the ambient air. *Journal of Aerosol Science* **2018**, *115*, 158-163. <http://www.sciencedirect.com/science/article/pii/S0021850217302239>
236. (U) Qiu, H.; Wu, J.; Hong, L.; Luo, Y.; Song, Q.; Chen, D., Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study. *The Lancet Infectious Diseases*. [https://doi.org/10.1016/S1473-3099\(20\)30198-5](https://doi.org/10.1016/S1473-3099(20)30198-5)
237. (U) Rabenau, H.; Kampf, G.; Cinatl, J.; Doerr, H., Efficacy of various disinfectants against SARS coronavirus. *Journal of Hospital Infection* **2005**, *61* (2), 107-111. <https://www.sciencedirect.com/science/article/pii/S0195670105000447>
238. (U) Rabenau, H. F.; Cinatl, J.; Morgenstern, B.; Bauer, G.; Preiser, W.; Doerr, H. W., Stability and inactivation of SARS coronavirus. *Med Microbiol Immunol* **2005**, *194* (1-2), 1-6. <https://link.springer.com/content/pdf/10.1007/s00430-004-0219-0.pdf>

239. (U) Radbel, J.; Narayanan, N.; Bhatt, P. J., Use of tocilizumab for COVID-19 infection-induced cytokine release syndrome: A cautionary case report. *Chest* **2020**.
240. (U) Rambaut, A., Phylodynamic analysis of nCoV-2019 genomes - 27-Jan-2020. <http://virological.org/t/phylodynamic-analysis-of-ncov-2019-genomes-27-jan-2020/353>.
241. (U) Rapid Expert Consultation, *Rapid Expert Consultation Update on SARS-CoV-2 Surface Stability and Incubation for the COVID-19 Pandemic (March 27, 2020)*. The National Academies Press: Washington, DC, 2020. <https://www.nap.edu/read/25763/chapter/1>
242. (U) Regalado, A., Blood tests show 14% of people are now immune to covid-19 in one town in Germany. *Technology Review* 2020.
243. (U) Remuzzi, A.; Remuzzi, G., COVID-19 and Italy: what next? *The Lancet* **2020**. [https://doi.org/10.1016/S0140-6736\(20\)30627-9](https://doi.org/10.1016/S0140-6736(20)30627-9)
244. (U) Ren, X.; Liu, Y.; Chen, H.; Liu, W.; Guo, Z.; Chen, C.; Zhou, J.; Xiao, Q.; Jiang, G.-M.; Shan, H., Application and Optimization of RT-PCR in Diagnosis of SARS-CoV-2 Infection. *medRxiv* **2020**.
245. (U) Rengasamy, S.; Eimer, B.; Shaffer, R. E., Simple respiratory protection--evaluation of the filtration performance of cloth masks and common fabric materials against 20-1000 nm size particles. *Ann Occup Hyg* **2010**, 54 (7), 789-98. <https://www.ncbi.nlm.nih.gov/pubmed/20584862>
246. (U) Richard, M.; Kok, A.; de Meulder, D.; Bestebroer, T. M.; Lamers, M. M.; Okba, N. M. A.; Fentener van Vlissingen, M.; Rockx, B.; Haagmans, B. L.; Koopmans, M. P. G.; Fouchier, R. A. M.; Herfst, S., SARS-CoV-2 is transmitted via contact and via the air between ferrets. *bioRxiv* **2020**, 2020.04.16.044503. <https://www.biorxiv.org/content/biorxiv/early/2020/04/17/2020.04.16.044503.full.pdf>
247. (U) Richardson, S.; Hirsch, J. S.; Narasimhan, M.; Crawford, J. M.; McGinn, T.; Davidson, K. W.; Consortium, a. t. N. C.-R., Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. *JAMA* **2020**. <https://doi.org/10.1001/jama.2020.6775>
248. (U) Richter, W.; Hofacre, K.; Willenberg, Z., *Final Report for the Bioquell Hydrogen Peroxide Vapor (HPV) Decontamination for Reuse of N95 Respirators*; Battelle Memorial Institute: 2016. <http://wayback.archive-it.org/7993/20170113034232/http://www.fda.gov/downloads/EmergencyPreparedness/Counterterrorism/MedicalCountermeasures/MCMRegulatoryScience/UCM516998.pdf>
249. (U) Riou, J.; Althaus, C. L., Pattern of early human-to-human transmission of Wuhan 2019 novel coronavirus (2019-nCoV), December 2019 to January 2020. *Eurosurveillance* **2020**, 25 (4), 2000058. <https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.4.2000058>
250. (U) Rivers, C.; Martin, E.; Watson, C.; Schoch-Spana, M.; Mullen, L.; Sell, T. K.; Gottlieb, S.; Warmbrod, K. L.; Hosangadi, D.; Kobokovich, A.; Potter, C.; Cicero, A.; Inglesby, T. V., *Public Health Principles for a Phased Reopening During COVID-19: Guidance for Governors*; Johns Hopkins Center for Health Security: 2020. https://www.centerforhealthsecurity.org/our-work/pubs_archive/pubs-pdfs/2020/reopening-guidance-governors.pdf
251. (U) Robertson, D., nCoV's relationship to bat coronaviruses & recombination signals (no snakes) **2020**. <http://virological.org/t/ncovs-relationship-to-bat-coronaviruses-recombination-signals-no-snakes/331>
252. (U) Rockx, B.; Kuiken, T.; Herfst, S.; Bestebroer, T.; Lamers, M. M.; Oude Munnink, B. B.; de Meulder, D.; van Amerongen, G.; van den Brand, J.; Okba, N. M. A.; Schipper, D.; van Run, P.; Leijten, L.; Sikkema, R.; Verschoor, E.; Verstrepen, B.; Bogers, W.; Langermans, J.; Drosten, C.; Fentener van Vlissingen, M.; Fouchier, R.; de Swart, R.; Koopmans, M.; Haagmans, B. L., Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model. *Science* **2020**, eabb7314. <https://science.sciencemag.org/content/sci/early/2020/04/16/science.abb7314.full.pdf>
253. (U) Romine, T., 'We need to fix it quickly.' Asymptomatic coronavirus cases at Boston homeless shelter raise red flag. *CNN* 2020.

254. (U) Rothe, C.; Schunk, M.; Sothmann, P.; Bretzel, G.; Froeschl, G.; Wallrauch, C.; Zimmer, T.; Thiel, V.; Janke, C.; Guggemos, W.; Seilmaier, M.; Drosten, C.; Vollmar, P.; Zwirgmaier, K.; Zange, S.; Wölfel, R.; Hoelscher, M., Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany. *New England Journal of Medicine* **2020**. <https://www.nejm.org/doi/full/10.1056/NEJMc2001468>

<https://www.nejm.org/doi/10.1056/NEJMc2001468>

255. (U) Ruan, Q.; Yang, K.; Wang, W.; Jiang, L.; Song, J., Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. *Intensive Care Medicine* **2020**.

<https://doi.org/10.1007/s00134-020-05991-x>

256. (U) Russell, T. W.; Hellewell, J.; Abbott, S.; Golding, N.; Gibbs, H.; Jarvis, C. I.; van Zandvoort, K.; group, C. n. w.; Flasche, S.; Eggo, R. M.; Edmunds, W. J.; Kucharski, A. J., Using a delay-adjusted case fatality ratio to estimate under-reporting. *CMMID*: 2020.

https://cmmid.github.io/topics/covid19/severity/global_cfr_estimates.html

257. (U) Sagonowsky, E., Swelling ranks of COVID-19 vaccines in human testing, Inovio doses its first patients. *Fierce Pharma* 2020.

258. (U) Saknimit, M.; Inatsuki, I.; Sugiyama, Y.; Yagami, K., Virucidal efficacy of physico-chemical treatments against coronaviruses and parvoviruses of laboratory animals. *Jikken Dobutsu* **1988**, *37* (3), 341-5. https://www.jstage.jst.go.jp/article/expanim1978/37/3/37_3_341/pdf

259. (U) Santarpia, J. L.; Rivera, D. N.; Herrera, V.; Morwitzer, M. J.; Creager, H.; Santarpia, G. W.; Crown, K. K.; Brett-Major, D.; Schnaubelt, E.; Broadhurst, M. J.; Lawler, J. V.; Reid, S. P.; Lowe, J. J., Transmission Potential of SARS-CoV-2 in Viral Shedding Observed at the University of Nebraska Medical Center. *medRxiv* **2020**, 2020.03.23.20039446.

<https://www.medrxiv.org/content/medrxiv/early/2020/03/26/2020.03.23.20039446.1.full.pdf>

260. (U) Schnirring, L., New coronavirus infects health workers, spreads to Korea.

<http://www.cidrap.umn.edu/news-perspective/2020/01/new-coronavirus-infects-health-workers-spreads-korea>.

261. (U) Schwartz, D. A., An analysis of 38 pregnant women with COVID-19, their newborn infants, and maternal-fetal transmission of SARS-CoV-2: maternal coronavirus infections and pregnancy outcomes. *Archives of Pathology & Laboratory Medicine* **2020**.

262. (U) Security, J. C. f. H., 2019-nCoV resources and updates on the emerging novel coronavirus. **2020**.

<http://www.centerforhealthsecurity.org/resources/2019-nCoV/>

263. (U) Shen, C.; Wang, Z.; Zhao, F.; Yang, Y.; Li, J.; Yuan, J.; Wang, F.; Li, D.; Yang, M.; Xing, L.; Wei, J.; Xiao, H.; Yang, Y.; Qu, J.; Qing, L.; Chen, L.; Xu, Z.; Peng, L.; Li, Y.; Zheng, H.; Chen, F.; Huang, K.; Jiang, Y.; Liu, D.; Zhang, Z.; Liu, Y.; Liu, L., Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. *JAMA* **2020**. <https://doi.org/10.1001/jama.2020.4783>

264. (U) Sheridan, C., Convalescent serum lines up as first-choice treatment for coronavirus. *Nature Biotechnology* 2020.

265. (U) Sheridan, C., Coronavirus and the race to distribute reliable diagnostics.

<https://www.nature.com/articles/d41587-020-00002-2>.

266. (U) Shi, J.; Wen, Z.; Zhong, G.; Yang, H.; Wang, C.; Huang, B.; Liu, R.; He, X.; Shuai, L.; Sun, Z.; Zhao, Y.; Liu, P.; Liang, L.; Cui, P.; Wang, J.; Zhang, X.; Guan, Y.; Tan, W.; Wu, G.; Chen, H.; Bu, Z., Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS–coronavirus 2. *Science* **2020**, eabb7015.

<https://science.sciencemag.org/content/sci/early/2020/04/07/science.abb7015.full.pdf>

267. (U) Shi, S.; Qin, M.; Shen, B.; Cai, Y.; Liu, T.; Yang, F.; Gong, W.; Liu, X.; Liang, J.; Zhao, Q.; Huang, H.; Yang, B.; Huang, C., Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. *JAMA Cardiology* **2020**. <https://doi.org/10.1001/jamacardio.2020.0950>

268. (U) So, L.; Smith, G., In four U.S. state prisons, nearly 3,300 inmates test positive for coronavirus -- 96% without symptoms. *Reuters* 2020.

269. (U) Song, J.-Y.; Yun, J.-G.; Noh, J.-Y.; Cheong, H.-J.; Kim, W.-J., Covid-19 in South Korea — Challenges of Subclinical Manifestations. *New England Journal of Medicine* **2020**.
<https://www.nejm.org/doi/full/10.1056/NEJMc2001801>
270. (U) Stewart, P.; Ali, I., Coronavirus clue? Most cases aboard U.S. aircraft carrier are symptom-free. *Reuters* **2020**.
271. (U) Su, H.; Yang, M.; Wan, C.; Yi, L.-X.; Tang, F.; Zhu, H.-Y.; Yi, F.; Yang, H.-C.; Fogo, A. B.; Nie, X.; Zhang, C., Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. *Kidney International*. <https://doi.org/10.1016/j.kint.2020.04.003>
272. (U) Su, Y. C.; Anderson, D. E.; Young, B. E.; Zhu, F.; Linster, M.; Kalimuddin, S.; Low, J. G.; Yan, Z.; Jayakumar, J.; Sun, L.; Yan, G. Z.; Mendenhall, I. H.; Leo, Y.-S.; Lye, D. C.; Wang, L.-F.; Smith, G. J., Discovery of a 382-nt deletion during the early evolution of SARS-CoV-2. *bioRxiv* **2020**, 2020.03.11.987222.
<https://www.biorxiv.org/content/biorxiv/early/2020/03/12/2020.03.11.987222.full.pdf>
273. (U) Sun, S.; Cai, X.; Wang, H.; He, G.; Lin, Y.; Lu, B.; Chen, C.; Pan, Y.; Hu, X., Abnormalities of peripheral blood system in patients with COVID-19 in Wenzhou, China. *Clinica Chimica Acta* **2020**, *507*, 174-180. <http://www.sciencedirect.com/science/article/pii/S0009898120301790>
274. (U) Sutton, D.; Fuchs, K.; D'Alton, M.; Goffman, D., Universal Screening for SARS-CoV-2 in Women Admitted for Delivery. *New England Journal of Medicine* **2020**.
<https://www.nejm.org/doi/full/10.1056/NEJMc2009316>
275. (U) Tan, W.; Lu, Y.; Zhang, J.; Wang, J.; Dan, Y.; Tan, Z.; He, X.; Qian, C.; Sun, Q.; Hu, Q.; Liu, H.; Ye, S.; Xiang, X.; Zhou, Y.; Zhang, W.; Guo, Y.; Wang, X.-H.; He, W.; Wan, X.; Sun, F.; Wei, Q.; Chen, C.; Pan, G.; Xia, J.; Mao, Q.; Chen, Y.; Deng, G., Viral Kinetics and Antibody Responses in Patients with COVID-19. *medRxiv* **2020**, 2020.03.24.20042382.
<https://www.medrxiv.org/content/medrxiv/early/2020/03/26/2020.03.24.20042382.full.pdf>
276. (U) The Novel Coronavirus Pneumonia Emergency Response Epidemiology, T., The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) — China, 2020. *China CDC Weekly* **2020**, *2*, 1-10. <http://weekly.chinacdc.cn//article/id/e53946e2-c6c4-41e9-9a9b-fea8db1a8f51>
277. (U) Thevarajan, I.; Nguyen, T. H. O.; Koutsakos, M.; Druce, J.; Caly, L.; van de Sandt, C. E.; Jia, X.; Nicholson, S.; Catton, M.; Cowie, B.; Tong, S. Y. C.; Lewin, S. R.; Kedzierska, K., Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19. *Nature Medicine* **2020**. <https://doi.org/10.1038/s41591-020-0819-2>
278. (U) Thomas, P. R.; Karriker, L. A.; Ramirez, A.; Zhang, J.; Ellingson, J. S.; Crawford, K. K.; Bates, J. L.; Hammen, K. J.; Holtkamp, D. J., Evaluation of time and temperature sufficient to inactivate porcine epidemic diarrhea virus in swine feces on metal surfaces. *Journal of Swine Health and Production* **2015**, *23* (2), 84.
279. (U) Thomas, P. R.; Ramirez, A.; Zhang, J.; Ellingson, J. S.; Myers, J. N., Methods for inactivating PEDV in Hog Trailers. *Animal Industry Report* **2015**, *661* (1), 91.
280. (U) To, K. K.-W.; Tsang, O. T.-Y.; Leung, W.-S.; Tam, A. R.; Wu, T.-C.; Lung, D. C.; Yip, C. C.-Y.; Cai, J.-P.; Chan, J. M.-C.; Chik, T. S.-H., Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. *The Lancet Infectious Diseases* **2020**.
281. (U) Toner, E., *Interim Estimate of the US PPE Needs for COVID-19*; Johns Hopkins Center for Health Security: 2020. <https://www.centerforhealthsecurity.org/resources/COVID-19/PPE/PPE-estimate.pdf>
282. (U) van der Sande, M.; Teunis, P.; Sabel, R., Professional and Home-Made Face Masks Reduce Exposure to Respiratory Infections among the General Population. *Plos One* **2008**, *3* (7). <Go to ISI>://WOS:000264065800020

283. (U) van Doremalen, N.; Bushmaker, T.; Morris, D. H.; Holbrook, M. G.; Gamble, A.; Williamson, B. N.; Tamin, A.; Harcourt, J. L.; Thornburg, N. J.; Gerber, S. I.; Lloyd-Smith, J. O.; de Wit, E.; Munster, V. J., Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. *New England Journal of Medicine* **2020**. <https://doi.org/10.1056/NEJMc2004973>
284. (U) van Doremalen, N.; Bushmaker, T.; Munster, V. J., Stability of Middle East respiratory syndrome coronavirus (MERS-CoV) under different environmental conditions. *Euro Surveill* **2013**, *18* (38).
285. (U) Verdict, Cepheid to develop automated molecular test for coronavirus. Verdict Medical Devices: 2020. <https://www.medicaldevice-network.com/news/cepheid-automated-test-coronavirus/>
286. (U) Wan, Y.; Shang, J.; Graham, R.; Baric, R. S.; Li, F., Receptor recognition by novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS. *Journal of Virology* **2020**, JVI.00127-20. <https://jvi.asm.org/content/jvi/early/2020/01/23/JVI.00127-20.full.pdf>
287. (U) Wang, B.; Wang, L.; Kong, X.; Geng, J.; Xiao, D.; Ma, C.; Jiang, X. M.; Wang, P. H., Long-term Coexistence of SARS-CoV-2 with Antibody Response in COVID-19 Patients. *J Med Virol* **2020**.
288. (U) Wang, D.; Hu, B.; Hu, C.; Zhu, F.; Liu, X.; Zhang, J.; Wang, B.; Xiang, H.; Cheng, Z.; Xiong, Y.; Zhao, Y.; Li, Y.; Wang, X.; Peng, Z., Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. *JAMA* **2020**. <https://doi.org/10.1001/jama.2020.1585>
- https://jamanetwork.com/journals/jama/articlepdf/2761044/jama_wang_2020_oi_200019.pdf
289. (U) Wang, D.; Wang, J.; Jiang, Q.; Yang, J.; Li, J.; Gao, C.; Jiang, H.; Ge, L.; Liu, Y., No Clear Benefit to the Use of Corticosteroid as Treatment in Adult Patients with Coronavirus Disease 2019 : A Retrospective Cohort Study. *medRxiv* **2020**, 2020.04.21.20066258. <https://www.medrxiv.org/content/medrxiv/early/2020/04/24/2020.04.21.20066258.full.pdf>
290. (U) Wang, W.; Xu, Y.; Gao, R.; Lu, R.; Han, K.; Wu, G.; Tan, W., Detection of SARS-CoV-2 in Different Types of Clinical Specimens. *JAMA* **2020**. <https://doi.org/10.1001/jama.2020.3786>
291. (U) Wang, Y.; Jiang, W.; He, Q.; Wang, C.; Wang, B.; Zhou, P.; Dong, N.; Tong, Q., A retrospective cohort study of methylprednisolone therapy in severe patients with COVID-19 pneumonia. *Signal Transduct Target Ther* **2020**, *5* (1), 57.
292. (U) Wang, Y.; Zhang, D.; Du, G.; Du, R.; Zhao, J.; Jin, Y.; Fu, S.; Gao, L.; Cheng, Z.; Lu, Q.; Hu, Y.; Luo, G.; Wang, K.; Lu, Y.; Li, H.; Wang, S.; Ruan, S.; Yang, C.; Mei, C.; Wang, Y.; Ding, D.; Wu, F.; Tang, X.; Ye, X.; Ye, Y.; Liu, B.; Yang, J.; Yin, W.; Wang, A.; Fan, G.; Zhou, F.; Liu, Z.; Gu, X.; Xu, J.; Shang, L.; Zhang, Y.; Cao, L.; Guo, T.; Wan, Y.; Qin, H.; Jiang, Y.; Jaki, T.; Hayden, F. G.; Horby, P. W.; Cao, B.; Wang, C., Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. *The Lancet*. [https://doi.org/10.1016/S0140-6736\(20\)31022-9](https://doi.org/10.1016/S0140-6736(20)31022-9)
293. (U) Watson, C.; Cicero, A.; Blumenstock, J.; Fraser, M., *A National Plan to Enable Comprehensive COVID-19 Case Finding and Contact*; Johns Hopkins Center for Health Security: 2020. https://www.centerforhealthsecurity.org/our-work/pubs_archive/pubs-pdfs/2020/a-national-plan-to-enable-comprehensive-COVID-19-case-finding-and-contact-tracing-in-the-US.pdf
294. (U) WCS, A Tiger at Bronx Zoo Tests Positive for COVID-19; The Tiger and the Zoo's Other Cats Are Doing Well at This Time. <https://newsroom.wcs.org/News-Releases/articleType/ArticleView/articleId/14010/A-Tiger-at-Bronx-Zoo-Tests-Positive-for-COVID-19-The-Tiger-and-the-Zoos-Other-Cats-Are-Doing-Well-at-This-Time.aspx> (accessed April 6, 2020).
295. (U) Wei, W. E.; Li, Z.; Chiew, C. J.; Yong, S. E.; Toh, M. P.; Lee, V. J., Presymptomatic transmission of SARS-CoV-2 - Singapore, January 23 - March 16, 2020. *Morbidity and Mortality Weekly Report* **2020**, *ePub* (1 April 2020). <https://www.cdc.gov/mmwr/volumes/69/wr/mm6914e1.htm>
296. (U) Weissman, D. N.; de Perio, M. A.; Radonovich, L. J., Jr, COVID-19 and Risks Posed to Personnel During Endotracheal Intubation. *JAMA* **2020**. <https://doi.org/10.1001/jama.2020.6627>
297. (U) Wetsman, N., FDA authorizes first antibody-based test for COVID-19. *The Verge* 2 April, 2020.

298. (U) Whitman, J. D.; Hiatt, J.; Mowrey, C. T.; al., e., Test performance evaluation of SARS-CoV-2 serological assays. *Unpublished Preprint* **2020**. https://www.dropbox.com/s/cd1628cau09288a/SARS-CoV-2_Serology_Manuscript.pdf?dl=0
299. (U) WHO, *COVID-19 Strategy Update*; World Health Organization: 2020. <https://www.who.int/publications-detail/strategic-preparedness-and-response-plan-for-the-new-coronavirus>
300. (U) WHO, Diagnostic detection of Wuhan coronavirus 2019 by real-time RTPCR -Protocol and preliminary evaluation as of Jan 13, 2020. https://www.who.int/docs/default-source/coronaviruse/wuhan-virus-assay-v1991527e5122341d99287a1b17c111902.pdf?sfvrsn=d381fc88_2 (accessed 01/26/2020).
301. (U) WHO, "Immunity passports" in the context of COVID-19; World Health Organization: 2020. <https://www.who.int/news-room/commentaries/detail/immunity-passports-in-the-context-of-covid-19>
302. (U) WHO, *Infection prevention and control during health care when novel coronavirus (nCoV) infection is suspected*; 2020. [https://www.who.int/publications-detail/infection-prevention-and-control-during-health-care-when-novel-coronavirus-\(ncov\)-infection-is-suspected-20200125](https://www.who.int/publications-detail/infection-prevention-and-control-during-health-care-when-novel-coronavirus-(ncov)-infection-is-suspected-20200125)
303. (U) WHO, Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases.
304. (U) WHO, *Modes of transmission of virus causing COVID-19: implications for IPC precaution recommendations*; World Health Organization: 2020. <https://www.who.int/news-room/commentaries/detail/modes-of-transmission-of-virus-causing-covid-19-implications-for-ipc-precaution-recommendations>
305. (U) WHO, Novel Coronavirus (2019-nCoV) Situation Report-5 25 January 2020. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200125-sitrep-5-2019-ncov.pdf?sfvrsn=429b143d_4.
306. (U) WHO, Novel Coronavirus (2019-nCoV) technical guidance: Laboratory testing for 2019-nCoV in humans. <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/laboratory-guidance>.
307. (U) WHO, Update on WHO Solidarity Trial – Accelerating a safe and effective COVID-19 vaccine. World Health Organization: 2020. <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-trial-accelerating-a-safe-and-effective-covid-19-vaccine>
308. (U) Wölfel, R.; Corman, V. M.; Guggemos, W.; Seilmaier, M.; Zange, S.; Müller, M. A.; Niemeyer, D.; Jones, T. C.; Vollmar, P.; Rothe, C.; Hoelscher, M.; Bleicker, T.; Brünink, S.; Schneider, J.; Ehmann, R.; Zwirgmaier, K.; Drosten, C.; Wendtner, C., Virological assessment of hospitalized patients with COVID-2019. *Nature* **2020**. <https://doi.org/10.1038/s41586-020-2196-x>
309. (U) Wolff, M. H.; Sattar, S. A.; Adegunrin, O.; Tetro, J., Environmental survival and microbicide inactivation of coronaviruses. In *Coronaviruses with special emphasis on first insights concerning SARS*, Springer: 2005; pp 201-212.
310. (U) Wong, M. C.; Javornik Cregeen, S. J.; Ajami, N. J.; Petrosino, J. F., Evidence of recombination in coronaviruses implicating pangolin origins of nCoV-2019. *bioRxiv* **2020**, 2020.02.07.939207. <https://www.biorxiv.org/content/biorxiv/early/2020/02/13/2020.02.07.939207.full.pdf>
311. (U) Wrapp, D.; Wang, N.; Corbett, K. S.; Goldsmith, J. A.; Hsieh, C.-L.; Abiona, O.; Graham, B. S.; McLellan, J. S., Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion Conformation. *bioRxiv* **2020**, 2020.02.11.944462. <https://www.biorxiv.org/content/biorxiv/early/2020/02/15/2020.02.11.944462.full.pdf>
312. (U) Wu, F.; Wang, A.; Liu, M.; Wang, Q.; Chen, J.; Xia, S.; Ling, Y.; Zhang, Y.; Xun, J.; Lu, L.; Jiang, S.; Lu, H.; Wen, Y.; Huang, J., Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. *medRxiv* **2020**, 2020.03.30.20047365. <https://www.medrxiv.org/content/medrxiv/early/2020/04/06/2020.03.30.20047365.full.pdf>

313. (U) Wu, J. T.; Leung, K.; Leung, G. M., Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. *The Lancet* **2020**. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(20\)30260-9/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30260-9/fulltext)
314. (U) Wu, L.-P.; Wang, N.-C.; Chang, Y.-H.; Tian, X.-Y.; Na, D.-Y.; Zhang, L.-Y.; Zheng, L.; Lan, T.; Wang, L.-F.; Liang, G.-D., Duration of antibody responses after severe acute respiratory syndrome. *Emerging infectious diseases* **2007**, *13* (10), 1562.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2851497/pdf/07-0576_finalD.pdf
315. (U) Wu, P.; Duan, F.; Luo, C.; Liu, Q.; Qu, X.; Liang, L.; Wu, K., Characteristics of Ocular Findings of Patients With Coronavirus Disease 2019 (COVID-19) in Hubei Province, China. *JAMA Ophthalmology* **2020**. <https://doi.org/10.1001/jamaophthalmol.2020.1291>
316. (U) Wyllie, A. L.; Fournier, J.; Casanovas-Massana, A.; Campbell, M.; Tokuyama, M.; Vijayakumar, P.; Geng, B.; Muenker, M. C.; Moore, A. J.; Vogels, C. B. F.; Petrone, M. E.; Ott, I. M.; Lu, P.; Lu-Culligan, A.; Klein, J.; Venkataraman, A.; Earnest, R.; Simonov, M.; Datta, R.; Handoko, R.; Naushad, N.; Sewanan, L. R.; Valdez, J.; White, E. B.; Lapidus, S.; Kalinich, C. C.; Jiang, X.; Kim, D. J.; Kudo, E.; Linehan, M.; Mao, T.; Moriyama, M.; Oh, J. E.; Park, A.; Silva, J.; Song, E.; Takahashi, T.; Taura, M.; Weizman, O.-E.; Wong, P.; Yang, Y.; Bermejo, S.; Odio, C.; Omer, S. B.; Dela Cruz, C. S.; Farhadian, S.; Martinello, R. A.; Iwasaki, A.; Grubaugh, N. D.; Ko, A. I., Saliva is more sensitive for SARS-CoV-2 detection in COVID-19 patients than nasopharyngeal swabs. *medRxiv* **2020**, 2020.04.16.20067835.
<https://www.medrxiv.org/content/medrxiv/early/2020/04/22/2020.04.16.20067835.full.pdf>
317. (U) Xinhua, China detects large quantity of novel coronavirus at Wuhan seafood market
http://www.xinhuanet.com/english/2020-01/27/c_138735677.htm.
318. (U) Xu, X.; Han, M.; Li, T.; Sun, W.; Wang, D.; Fu, B.; Zhou, Y.; Zheng, X.; Yang, Y.; Li, X.; Zhang, X.; Pan, A.; Wei, H., Effective treatment of severe COVID-19 patients with tocilizumab. *Proceedings of the National Academy of Sciences* **2020**, 202005615.
<https://www.pnas.org/content/pnas/early/2020/04/27/2005615117.full.pdf>
319. (U) Xu, Z.; Shi, L.; Wang, Y.; Zhang, J.; Huang, L.; Zhang, C.; Liu, S.; Zhao, P.; Liu, H.; Zhu, L.; Tai, Y.; Bai, C.; Gao, T.; Song, J.; Xia, P.; Dong, J.; Zhao, J.; Wang, F.-S., Pathological findings of COVID-19 associated with acute respiratory distress syndrome. *The Lancet Respiratory Medicine*.
[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(20\)30260-9/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30260-9/fulltext)
320. (U) Xue, K. S.; Bloom, J. D., Reconciling disparate estimates of viral genetic diversity during human influenza infections. *Nature Genetics* **2019**, *51* (9), 1298-1301. <https://doi.org/10.1038/s41588-019-0349-3>
321. (U) Yan, C. H.; Faraji, F.; Prajapati, D. P.; Boone, C. E.; DeConde, A. S., In *Association of chemosensory dysfunction and Covid-19 in patients presenting with influenza-like symptoms*, International Forum of Allergy & Rhinology, Wiley Online Library: 2020.
322. (U) Yang, H.; Wang, C.; Poon, L., Novel coronavirus infection and pregnancy. *Ultrasound in Obstetrics & Gynecology* **2020**.
323. (U) Yang, P.; Qi, J.; Zhang, S.; Bi, G.; Wang, X.; Yang, Y.; Sheng, B.; Mao, X., Feasibility of Controlling COVID-19 Outbreaks in the UK by Rolling Interventions. *medRxiv* **2020**, 2020.04.05.20054429.
<https://www.medrxiv.org/content/medrxiv/early/2020/04/07/2020.04.05.20054429.full.pdf>
324. (U) Yu, N.; Li, W.; Kang, Q.; Zeng, W.; Feng, L.; Wu, J., No SARS-CoV-2 detected in amniotic fluid in mid-pregnancy. *The Lancet Infectious Diseases*. [https://doi.org/10.1016/S1473-3099\(20\)30320-0](https://doi.org/10.1016/S1473-3099(20)30320-0)
325. (U) Yu, W.-B.; Tang, G.-D.; Zhang, L.; Corlett, R. T., Decoding evolution and transmissions of novel pneumonia coronavirus using the whole genomic data. *ChinaXiv* **2020**.
<http://www.chinaxiv.org/abs/202002.00033>
326. (U) Zhang, J.; Litvinova, M.; Liang, Y.; Wang, Y.; Wang, W.; Zhao, S.; Wu, Q.; Merler, S.; Viboud, C.; Vespignani, A.; Ajelli, M.; Yu, H., Changes in contact patterns shape the dynamics of the COVID-19

outbreak in China. *Science* **2020**, eabb8001.

<https://science.sciencemag.org/content/sci/early/2020/05/04/science.abb8001.full.pdf>

327. (U) Zhang, J.; Litvinova, M.; Wang, W.; Wang, Y.; Deng, X.; Chen, X.; Li, M.; Zheng, W.; Yi, L.; Chen, X.; Wu, Q.; Liang, Y.; Wang, X.; Yang, J.; Sun, K.; Longini, I. M., Jr.; Halloran, M. E.; Wu, P.; Cowling, B. J.; Merler, S.; Viboud, C.; Vespignani, A.; Ajelli, M.; Yu, H., Evolving epidemiology and transmission dynamics of coronavirus disease 2019 outside Hubei province, China: a descriptive and modelling study. *The Lancet Infectious Diseases*. [https://doi.org/10.1016/S1473-3099\(20\)30230-9](https://doi.org/10.1016/S1473-3099(20)30230-9)

328. (U) Zhang, Q.; Zhang, H.; Huang, K.; Yang, Y.; Hui, X.; Gao, J.; He, X.; Li, C.; Gong, W.; Zhang, Y.; Peng, C.; Gao, X.; Chen, H.; Zou, Z.; Shi, Z.; Jin, M., SARS-CoV-2 neutralizing serum antibodies in cats: a serological investigation. *bioRxiv* **2020**, 2020.04.01.021196.

<http://biorxiv.org/content/early/2020/04/03/2020.04.01.021196.abstract>

329. (U) Zhao; Musa; Lin; Ran; Yang; Wang; Lou; Yang; Gao; He; Wang, Estimating the Unreported Number of Novel Coronavirus (2019-nCoV) Cases in China in the First Half of January 2020: A Data-Driven Modelling Analysis of the Early Outbreak. *Journal of Clinical Medicine* **2020**, *9* (2), 388.

330. (U) Zhao, G.; Jiang, Y.; Qiu, H.; Gao, T.; Zeng, Y.; Guo, Y.; Yu, H.; Li, J.; Kou, Z.; Du, L.; Tan, W.; Jiang, S.; Sun, S.; Zhou, Y., Multi-Organ Damage in Human Dipeptidyl Peptidase 4 Transgenic Mice Infected with Middle East Respiratory Syndrome-Coronavirus. *PLoS One* **2015**, *10* (12), e0145561.

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4689477/pdf/pone.0145561.pdf>

331. (U) Zhao, J.; Yuan, Q.; Wang, H.; Liu, W.; Liao, X.; Su, Y.; Wang, X.; Yuan, J.; Li, T.; Li, J.; Qian, S.; Hong, C.; Wang, F.; Liu, Y.; Wang, Z.; He, Q.; He, B.; Zhang, T.; Ge, S.; Liu, L.; Zhang, J.; Xia, N.; Zhang, Z., Antibody Responses to SARS-CoV-2 in Patients of Novel Coronavirus Disease 2019. *SSRN* **2020**.

https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3546052#

332. (U) Zhen-Dong, T.; An, T.; Ke-Feng, L.; Peng, L.; Hong-Ling, W.; Jing-Ping, Y.; Yong-Li, Z.; Jian-Bo, Y., Potential Presymptomatic Transmission of SARS-CoV-2, Zhejiang Province, China, 2020. *Emerging Infectious Disease journal* **2020**, *26* (5). https://wwwnc.cdc.gov/eid/article/26/5/20-0198_article

333. (U) Zhongchu, L., The sixth press conference of "Prevention and Control of New Coronavirus Infected Pneumonia". Hubei Provincial Government: 2020.

http://www.hubei.gov.cn/hbfb/xwfbh/202001/t20200128_2015591.shtml

334. (U) Zhou, F.; Yu, T.; Du, R.; Fan, G.; Liu, Y.; Liu, Z.; Xiang, J.; Wang, Y.; Song, B.; Gu, X.; Guan, L.; Wei, Y.; Li, H.; Wu, X.; Xu, J.; Tu, S.; Zhang, Y.; Chen, H.; Cao, B., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *The Lancet*.

[https://doi.org/10.1016/S0140-6736\(20\)30566-3](https://doi.org/10.1016/S0140-6736(20)30566-3)

335. (U) Zhou, H.; Chen, X.; Hu, T.; Li, J.; Song, H.; Liu, Y.; Wang, P.; Liu, D.; Yang, J.; Holmes, E. C.; Hughes, A. C.; Bi, Y.; Shi, W., A novel bat coronavirus reveals natural insertions at the S1/S2 cleavage site of the Spike protein and a possible recombinant origin of HCoV-19. *bioRxiv* **2020**, 2020.03.02.974139.

<https://www.biorxiv.org/content/biorxiv/early/2020/03/11/2020.03.02.974139.full.pdf>

336. (U) Zhou, P.; Yang, X.-L.; Wang, X.-G.; Hu, B.; Zhang, L.; Zhang, W.; Si, H.-R.; Zhu, Y.; Li, B.; Huang, C.-L.; Chen, H.-D.; Chen, J.; Luo, Y.; Guo, H.; Jiang, R.-D.; Liu, M.-Q.; Chen, Y.; Shen, X.-R.; Wang, X.; Zheng, X.-S.; Zhao, K.; Chen, Q.-J.; Deng, F.; Liu, L.-L.; Yan, B.; Zhan, F.-X.; Wang, Y.-Y.; Xiao, G.; Shi, Z.-L., Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin. *bioRxiv* **2020**, 2020.01.22.914952.

<https://www.biorxiv.org/content/biorxiv/early/2020/01/23/2020.01.22.914952.1.full.pdf>

337. (U) Zhu, Y.; Chen, Y. Q., On a Statistical Transmission Model in Analysis of the Early Phase of COVID-19 Outbreak. *Statistics in Biosciences* **2020**, 1-17.

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113380/>

338. (U) Zou, L.; Ruan, F.; Huang, M.; Liang, L.; Huang, H.; Hong, Z.; Yu, J.; Kang, M.; Song, Y.; Xia, J.; Guo, Q.; Song, T.; He, J.; Yen, H.-L.; Peiris, M.; Wu, J., SARS-CoV-2 Viral Load in Upper Respiratory Specimens

of Infected Patients. *New England Journal of Medicine* 2020.
<https://www.nejm.org/doi/full/10.1056/NEJMc2001737>

